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ABSTRACT 
 
PART I. Investigation of Small Molecule Binding to an RNA Hairpin Loop 
Containing a Dangling End 
PART II. Unraveling the Interaction of Pathogenic RNAs with the MBNL1 Protein 
and Complex Inhibition by Small Molecules 
 
PART I. RNA plays important and versatile roles in gene expression by both carrying and 
regulating the information used to direct protein synthesis. Therefore, small molecules able to 
bind to RNA and alter these biological processes would be of great utility. This part of my thesis 
describes the virtual screening and identification of a quinoline derivative binding cooperatively 
to a GCAA RNA tetraloop containing a 3’ dangling end (tGCAA). The compound NSC5485 
(QD2) was identified by performing a similarity search of the NCI database of 250,000 
compounds and using the program AutoDock 3. Fluorescence and ITC experiments revealed that 
QD2 binds cooperatively to four identical binding sites on tGCAA RNA hairpin. The 
equilibrium binding dissociation constant of the four identical binding sites is 8.2 (±0.4) µM. CD 
spectroscopy and UV titration experiments suggested that binding of QD2 changes the 
conformation of RNA and perturbs the QD2 chromophore. 
PART II. Trinucleotide repeat expansions are the genetic cause of numerous human diseases, 
including Huntington’s disease, Fragile X mental retardation, and myotonic dystrophy type 1. 
Myotonic dystrophy (DM1 and DM2) is an autosomal dominant neuromuscular disorder 
associated with a (CTG)n and (CCTG)n expansion in the 3’-untranslated region of the Dystrophia 
Myotonica protein kinase (DMPK) gene. The disease is characterized by a waning of the 
muscles (muscular dystrophy), eye-lens opacity and myotonia. The pathogenic poly(CUG)RNA 
and poly(CCUG)RNA binds to and sequesters key proteins, such as MBNL1 (muscleblind-like 
 iii 
protein 1), preventing them from regulating proper splicing of different pre-mRNAs. The 
severity of disease correlates with the length of the repeat tract in peripheral blood.  
 The first part of this project is about investigating the interaction of the MBNL1N protein 
with poly(CUG)RNA. We are interested in identifying important amino acids or zinc finger 
domains involved in recognition of MBNL1N protein to poly(CUG)RNA. To address this 
question we did alanine scanning for six amino acids and expressed truncated versions of the 
protein and studied their interaction with MBNL1N protein by gel-shift assays. In the second 
part, the inhibition of complexes formed between the toxic poly(CUG)RNA or poly(CCUG) 
RNA with MBNL1 protein by a small molecules has been shown by gel-shift assays. We 
identified small molecules containing triaminotriazine-acridine and triaminopyrimidine-acridine 
conjugates which can specifically inhibit (CUG)12 and (CCUG)6 complexes with MBN1N 
protein, respectively. Thus the compounds triaminotriazine-acridine and triaminopyrimidine-
acridine conjugates are potential lead compounds for targeting DM1 and DM2, respectively. 
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CHAPTER 1 
RNA as Target for Small Molecules 
1.1 Introduction   
RNA plays essential roles in gene replication, transcription and translation, which direct 
protein synthesis in living organisms.1-3 RNA also plays important roles in catalyzing the 
maturation of mRNAs via ribozymes, and these are highly regulated by various 
ribonucleoprotein (RNP)-RNA interactions.4-5 RNA has some advantages as a drug target 
compared to targeting traditional protein targets because of sequence specific binding, selective 
inhibition, more sites available for interaction, multivalent drug targeting, and difficulty in 
mutating RNA.5 RNAs fold into various structures that form binding sites for proteins and other 
RNAs, and are important for the correct functioning of RNA.6-8 New opportunities in the field of 
drug discovery have been created because of recent advances in the fields of RNA synthesis, 
structure determination, and therapeutic target identification. The structural flexibility of RNA is 
useful in creating different possible secondary and tertiary structures and allows structure-
specific as well as sequence-specific recognition of RNA by small molecules.9 Small molecules 
that bind to bacterial ribosomal RNA and inhibit protein synthesis are available as potential 
antibiotics.10-11 The structural diversity and the importance in the cellular function of RNA may 
make it a therapeutic target for treating many diseases. Therefore, small molecules that bind to 
RNA and affect any of these biological processes would be of great utility.12-14 
1.2 RNA structural motifs 
In general, RNA folds in so that complementary sequences form double helices and the 
possible secondary structures are shown in Figure 1-1. These hairpin loop, bulge, and internal 
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loop secondary structures are useful for the formation of tertiary structures via interactions of 
preformed structures that precisely present chemical moieties that are essential for the function 
of RNA as a biological catalyst, translator of genetic information, and structural scaffold.15 
Secondary structure motifs can be divided into two classes: local structural motifs and global 
structural motifs. The local motifs influence RNA structure only in their immediate vicinity but 
may be involved in tertiary interactions. Conversely, RNA global structural motifs distort the 
relationship between helices by unwinding and/or bending/kinking or by involvement in tertiary 
interactions. These tertiary interactions which are formed between distinct secondary structural 
elements play a dominant role in establishing the global fold of the structure.16 The hydrogen 
bonding interaction of the 2’-hydroxyl group,  base stacking, binding of divalent metal cations, 
noncanonical base pairing, and back bone topology all serve to stabilize the global structure of 
RNA. The growth in analyzing the structure of RNA has led to the discovery of many secondary 
and tertiary motifs, including pseudoknots, ribose zippers, tetraloop motifs, adenine platforms, 
G-ribo motifs, A minor motifs, base triplexes, and metal core motifs.15, 17-18 These diverse RNA 
structural motifs may be targets for small molecules. 
 
 
 
 
 
 
                                Duplex         Bulge        Internal loop    Stem loop 
  Figure 1-1. Common RNA secondary structural elements.  
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1.3 RNA binding pockets for small molecule binding 
In designing small molecules to bind RNA, it is useful to consider the similarities and 
differences between recognition of RNA and recognition of DNA and proteins.  RNA has an A-
form helical conformation with a shallow, wide minor groove and a narrow, deep major groove. 
This structure makes small molecules binding in the major and minor groves of RNA difficult 
compared to binding DNA. Studies performed by Crothers suggested that the fully base paired 
A-form helix of the major groove is only 4 0A wide, which precludes much small molecule 
binding.19 The 2’-hydroxyl group present in the minor groove of RNA results in a puckering of 
the ribose group, leading to a change in the helix pitch and a tilt of the bases. Phosphate groups 
are displayed mostly in the major groove. Un- or mis-matched bases in RNA duplexes widen the 
major groove and provide surface-exposed pockets favorable for ligand binding. The binding 
pockets that are formed by various RNA secondary and tertiary structures provide the basis for 
selective targeting of RNA with protein and small molecule ligands.13 These structured sites 
bring appropriate groups into the correct topology to selectively recognize and interact with 
complementary groups on the small molecule in a manner very similar to the shape dependent 
interactions of small molecules with proteins. 
1.4 Molecular recognition of RNA by small molecules 
There are several different ways for a molecule to interact with RNA. Non-covalent or 
reversible interactions play a substantial role in determining binding specificity. Electrostatic 
interactions with the phosphate backbone are ideal nonspecific interactions and are commonly 
observed in most small molecule-RNA complexes. These interactions are important for 
enhancing the binding of small molecules and generally occur along the exterior of the helix. 
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A second mode of binding is groove-bound association. This interaction involves direct 
hydrogen bonding or van der Waals interaction with the nucleic acid base in the deep major 
groove or shallow minor groove of the RNA helix. The hydroxyl and amine groups of 
aminoglycosides form hydrogen bonds with RNA backbone and play important roles in RNA 
binding of aminoglycosides. The electrostatic and groove-binding modes don’t require a change 
in the conformation, but alteration in the structure of RNA is possible upon binding.20  
The third type of binding mode is intercalation, which is observed between aromatic 
ligands and RNA bases. This binding mode requires a distortion of RNA helix, in order to 
accommodate the binding ligand. Stacking interactions are relatively non-specific, but diverse 
functional groups can be introduced into the stacked scaffolds in order to render binding 
specificity. These stacking interactions were observed in several aminoglycoside-RNA 
complexes as binding between sugar ring and RNA bases. 
1.5 RNA-small molecule binding 
Research in the field of targeting RNA has increased after the success of aminoglycoside 
antibiotics, which target ribosomes and specifically ribosomal RNA in a number of 
microorganisms. The aminoglycosides continue to provide very important paradigms for 
understanding RNA recognition. A number of highly specific RNA-small molecule complexes 
have been recently reviewed by Jason Thomas and Paul Hergenrother.13 In recent years, three 
new classes of RNA molecules have been identified as drug targets. The first class is catalytic 
RNA molecules or ribozymes, which include the hammerhead ribozyme, and self splicing group 
I introns. The second class, called aptamers is comprised of sequences that have been selected in 
vitro for specific and high affinity binding. The third class is RNA targets containing protein 
binding sites, include TAR (trans-activating region), and RRE (Rev responsive element) of HIV.  
  
5
RNA is also an attractive target for a number of emerging human diseases that are caused by 
RNA viruses including HIV and hemorrhagic fever viruses such as dengue and Ecoalb21 and 
controlling various biological functions. There has been some success in the development of 
agents that target the TAR and RRE hairpins that control HIV replication. Recently determined 
structures of the RNA modules involved in unique RNA functions, such as ribozymes in 
splicing, have revealed targets for the development of drugs that inhibit cellular functions at very 
important steps.22  
Small molecules have been shown to be able to recognize diverse RNA structural motifs 
such as duplexes, loops, bulges, and pseudoknots. The main objective of the work described in 
this thesis is the targeting of RNA hairpins and mismatches, including tetra-loops containing 
dangling ends and U-U mismatches in RNA duplexes. Small molecules targeted to various RNA 
structural motifs will be briefly reviewed in the following discussion. 
1.5.1 Duplex binders 
Small molecules may bind to the duplex region of RNA through intercalation or groove 
binding. Intercalation occurs between the base pairs and is governed by stacking interactions. 
Groove binding is governed by shape complementarity and hydrogen bonding, although charge 
and steric effects are also observed to play roles in groove binding. Groove binders can be 
further divided into two subclasses: minor groove binders and major groove binders.  
The most potent aminoglycoside antibiotic neomycin (1, Figure 1-2), was shown to bind 
to the lower stem of the HIV-1 TAR RNA.23 This was confirmed by NMR data obtained for the 
HIV-1 TAR RNA-Neomycin B complex, which showed that neomycin binds to the minor 
groove of the TAR lower stem. This binding site is quite unusual because aminoglycosides 
generally bind in the major groove of other RNA targets.24 Another aminoglycoside derivative, 
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tobramycin (2, Figure 1-2), was found to bind to the major groove of polymeric RNA duplex 
poly(rI).poly(rC), which exhibits characteristic A-type conformation. A combination of 
spectroscopic, calorimetric, viscometric, and computer modeling techniques characterized the 
binding of tobramycin to duplex RNA.25 
2-Phenylquinoline derivatives (3, Figure 1-2) were shown to bind to poly A-U RNA 
duplex by intercalation. The substituent at position X controls the affinity of the binding. Highest 
affinity of binding was observed when the piperazyl substituent is at the para position.26 Kinetic 
and modeling results suggest that para-substituted phenylquinoline binds to duplex RNA by 
threading intercalation while the ortho- and meta- substituted phenylquinoline bind to duplex 
RNA by classical intercalation. Threading intercalation is a useful strategy for enhanced affinity 
and specificity.27 Wilson and coworkers showed that most of their diphenylfuran derivatives (4, 
Figure 1-2) binds to a poly A-U RNA duplex by intercalation instead of by association with the 
minor groove, even though diphenylfurans recognize the poly A-T DNA duplex by association 
with the minor groove.28  
 
 
 
 
 
 
 
 
Figure 1-2. Small molecules binding to RNA duplexes. 
4 a 
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 1.5.2 External loop or Hairpin binders 
Hairpin loops are the most abundant secondary structures after the duplex region.29 
Hairpin loops are formed when a sequence folds back on it self to form a duplex that is linked 
through a single strand of nucleotides. These are also called stem loops. The loop size varies 
based on the number of unpaired bases present in the single strand. The stability is controlled by 
the loop size; hexa- and hepta loops have been determined to be the favored loop size because 
six to seven nucleotides is of ideal length to span for A-form helix. These loops mainly provide 
sites of nucleation for RNA folding and participate in RNA-protein and RNA-RNA 
interactions.30 
Figure 1-3. RNA hairpin loop binders. 
Despite the importance of loops only few small molecules have been shown to bind stem 
loops of any size or sequence. Mei and co workers were the first to find out a small molecule (5, 
Figure 1-3) with demonstrated affinity to hairpin loops. This compound was showed to bind to 
loop region of TAR RNA (A, Figure 1-4) which inhibited the interaction between Tat and TAR 
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of HIV virus.31 Our laboratory investigated the binding of small molecule (6, Figure 1-3) to stem 
loop 2 of U1A snRNA (B, Figure 1-4) which interact with U1A protein in the spliceosome. This 
compound was shown to inhibit the U1A-RNA complex with an IC50 of 1.0 µM.32 Our laboratory 
also investigated a series of commercially available RNA-binding compounds, that were 
identified by computational docking and found to bind the GNRA tetraloop (C, Figure 1-4) and 
stem loop 3 RNA of the packaging signal Ψ of HIV-1 (D, Figure 1-4).33-35 Compounds 7 and 8 
(Figure 1-3) were reported to bind the GNRA tetraloop and stem loop 3 RNA with binding 
constant 0.7 µM and 1.4 µM, respectively.  
Hergenrother and co-workers designed 2-deoxystreptamine (DOS) dimers, compounds 9, 
10, 11, and 12 (Figure 1-3) and investigated their binding to various hairpin loop structures (E-
H, Figure 1-4). In one study, compound 9 was found to bind to E, F, G, and H (Figure 1-4) 
hairpin RNAs with 34 µM, 11 µM, 11 µM, and 8 µM dissociation constants, respectively.36 
Compound 11 and 12 were found to be selective towards tetraloops and octaloops, respectively, 
and bound with weaker affinity to other RNA hairpins and double stranded RNA.37 
 
 
 
 
 
 
 
 
Figure 1-4. RNA hairpin loop structures used for the discovery of various stem loop binders. 
  
9
1.5.3 Internal loop binders 
Internal loops can involve symmetric or asymmetric loops within the duplex. These loops 
contain one (mismatch loop) or more unpaired or mispaired bases on each strand of duplex. 
These sites generally serve to make the major groove of the RNA more accessible, and they can 
also more easily undergo conformational changes when bound to ligands compared to duplex 
RNA.19 Small molecules binding to internal loops in the 16S A-site rRNA, RRE RNA, and 
thymidylate synthase mRNA has been extensively studied.13  
After the initial discovery of aminoglycoside antibiotics, which target 16S A-site rRNA, 
scientists modified them to make better drugs with less toxicity and more activity. Wong and co-
workers synthesized a library of bifunctional aminoglycosides by dimerizing neamine (13, 
Figure 1-5) to overcome the problem of aminoglycoside-modifying enzymes.38 A series of alkyl-
linked neamine dimers of varying tether lengths linked through amide or carbamate linkages 
were synthesized. Compound 14 (KD = 0.04 µM) (Figure 1-5) binds with higher affinity to 16S 
A-site over neamine (KD = 10 µM). After this initial success with neamine dimers, simple sugars 
were dimerized including 2-deoxystreptamine (DOS), 6’-aminoglucosamine, and glucosamine, 
which are the core building blocks of neamine and paromamine ring systems.39 The binding of 
these molecules to the 16S A site was studied by ESI-MS. The dimers were found to bind better 
than respective monomers to 16S A-site, but not better than neamine dimers. Mobashery and co-
workers identified some of the neamine derivatives with enhanced binding affinity for 16S A-site 
RNA and reduced the susceptibility to aminoglycoside modifying enzymes using a 
computational approach.40 Boons and co-workers synthesized a series of neamine mimics by 
replacing the sugar units with various disaccharides. In order to identify mimics of 
aminoglycosides that are more synthetically tractable for chemical optimization, Ding and co-
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workers synthesized a library of heterocyclic 2-deoxystreptamine conjugates substituted at the 4-
positon.41 
 
Figure 1-5. RNA internal loop binders 
 
The diphenylfuran derivative (4 a, Figure 1-2) was found to bind to the HIV-1 RRE RNA 
internal loop by a threading intercalating mode.42 Chemical foot-printing experiments revealed 
that it bound to the RRE RNA more strongly than to the duplex RNA. It was proposed that this 
compound binds to the G-C base pair just below the critical internal loop to exert its inhibitory 
effects. In contrast, another diphenylfuran derivative (4 b, Figure 1-2) was shown to selectively 
recognize the poly A-U duplex. This shows the possibility of tuning binding specificity by 
changing the substituents of the diphenylfuran scaffold.  
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Tor and co-workers enhanced the affinity and specificity of the interaction of 
aminoglycosides with RRE by replacing the amino group with guanidinium group.43 Tor and co-
workers also developed aminoglycosides conjugated with an acridine intercalator.44 The acridine 
conjugate and guanidinoglycoside of neomycin (15, 16 Figure 1-5) inhibited the Rev-RRE 
complex with IC50 value of 0.04 µM and 0.8 µM, respectively, which is better than neomycin (1, 
Figure 1-2, IC50 7.0 µM). Cho and co-workers screened various DNA intercalators and minor 
groove binding compounds (Hoechst 33258, DAPI, distamycin A) for their ability to bind to 
thymidylate synthase mRNA. Hoechst 33258 compound is the most effective compound with a 
binding constant of 60 nM. In general the groove binding compounds bound better than 
intecalators.45 
1.5.4 Bulge binders 
Bulges are formed when there are an unequal number of bases in the duplex strands. The 
unpaired nucleotide in a single base bulge can either stack in the duplex or loop out into solution 
depending on the base composition. Bulges are always destabilizing towards duplex formation 
and become more destabilizing with increasing of bulge size.46-47 Weeks and Crothers have 
suggested that certain base bulges will lead to a greater major groove accessibility, thus creating 
sites for binding by proteins and small molecules.48 The most commonly targeted RNA bulges 
are the trans activating region (TAR) RNA, IRE (iron response element) RNA, and T-box RNA. 
The initial success of the binding of ethidium to TAR RNA lead Baily and co-workers to 
examine the ability of several intercalators (ethidium, proflavine), DNA minor groove 
compounds (DAPI, netropsin, berenil, and Hoechst 33285), and a threading intercalator 
(amsacrine-4-carboxamide derivative SN16713) (17, Figure 1-6) to bind TAR RNA. All of the 
compounds bound to TAR except netropsin (18, Figure 1-6), with intercalative mode of 
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binding.49 An aminoquinoline derivative was discovered from high throughput screening to 
inhibit the Tat-TAR interaction by binding to the same bulge where the Tat protein binds.23 This 
compound bound to RNA using stacking interactions and hydrogen bonds and has a relatively 
low molecular weight.4, 50 A 3, 4, 5-trisubtituted oxazolidinone library was evaluated for their 
binding with T-box RNA because of their low charge, which showed decrease non-specific 
interactions with RNA.51 The natural product yohimbine (19, Figure 1-6) was determined to bind 
to multiple secondary structures of the fIRE, which prevent the binding of IRP to IRE and 
increase the levels of ferritin protein by increasing the translation process.52 
 
Figure 1-6. Examples for RNA bulge binders 
1.6 Affinity vs specificity  
Affinity describes how strongly a ligand binds to its target, while specificity is a measure of 
how preferentially a ligand binds to a target molecule over other molecules. The ligands 
designed for targeting RNA need to bind RNA with both affinity and specificity. The affinity of 
ligands binding to RNA targets can be increased by conjugating ligands having two different 
binding modes44, 57-58, or by designing dimerized ligands.36-37, 59 Tor and co-workers enhanced the 
affinity and specificity of aminoglycosides interaction with RRE by replacing the amino group 
with guanidinium group.43 The same group also designed a series of acridine conjugated 
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aminoglycosides and aminoglycoside dimers that bind to the HIV-1 RRE RNA with high 
affinity.44, 60 They also designed a series neomycin-acridine conjugates that bind to the HIV-1 
RRE RNA with varied linker length that is a good example of increasing specificity of ligands. 
The neo-acridine with shortest linker prefers the RRE RNA, the longest linker prefers duplex 
DNA and the intermediate linker prefers duplex RNA. These results shows that the specificity 
can be controlled by the linker length and affinity can be enhanced by the conjugation strategy. 
Compared to neomycin-acridine conjugates the tobramycin-acridine and kanamycin-
acridine conjugates have slightly lower affinity for RRE but higher specificity for the RRE, 
which suggests that there is an inverse relationship between affinity and specificity. Thus 
designing ligands with high affinity and specificity is possible, but achieving both in one design 
is a difficult task. Although improved affinity and specificity were obtained using 
aminoglycoside dimers, aminoglyside-acridine conjugates, and guanidinoglycosides strategies, a 
drawback of these approaches is that the molecules become larger, and thus, are not as useful as 
drug leads. 
1.7 Conclusion 
The knowledge of RNA-small molecule recognition is important to design and synthesize 
specific RNA binders. Thus far, it has been demonstrated that ligands generally bind to RNA by 
taking advantage of specific RNA structures, such as internal loops and base bulges, in which the 
deep and narrow major groove has become accessible for binding interactions. The recognition 
of RNA targets by their natural ligands with high specificity involves a multitude of functional 
groups.  Furthermore, ligands may exploit the regions of flexibility in the RNA, in which the 
binding site can be adapted for specific and tight binding by a small molecule. Because proteins 
appear to use similar rules for binding of RNA, the natural protein binding sites may be desirable 
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targets for drug design. Both natural products and designed ligands can be used to exploit 
structure-specific recognition in the same way that protein or other biological effectors (e. g., 
antibiotics) bind to RNA. Thus, knowledge of the structural basis of these RNA-ligand 
interactions will ultimately provide an impetus for rational drug discovery.    
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CHAPTER 2 
Cooperative Binding of a Quinoline Derivative to an RNA Hairpin 
Loop Containing a Dangling End 
2.1 Introduction  
As discussed in the introduction, RNA plays essential roles in gene replication, 
transcription, and translation, which direct protein synthesis in living organisms.1-3 Therefore, 
small molecules that bind to RNA and affect any of these biological processes would be of great 
utility.4-7 RNA hairpin secondary structures, form target sites for both proteins and other RNAs, 
and are the most abundant form of secondary structure after the helix.8-15 However, there have 
been few studies to investigate small molecule binding to RNA hairpins.7 Among the different 
types of hairpins, tetraloops (four nucleotide stem loop structures) are abundant in ribosomal 
RNA. Studies have shown that 55% of hairpins are tetraloops in 16S rRNA whereas, pentaloops 
account only for 13% of the total loops and a similar pattern was observed in 23S rRNA. GNRA, 
UNCG, (U/A)GNN, GGNG, and CUUG (N stands for any nucleotide, R stands for purine and Y 
stands for pyrimidine) sequences are conserved among different possible tetraloop sequences.17-
18 GNRA and UNCG are the most common tetraloops in ribosomal RNA and have unusual 
thermodynamic stabilities.19-20 GNRA tetraloops are known to play important roles in 
maintaining tertiary contacts in ribosomal RNA,9, 10 catalytic RNA,8, 11, 13, 21 and the viral internal 
ribosome entry site (IRES).22, 23 These RNAs are also known to interact with proteins such as 
SRP proteins, ribosomal proteins, elongation factors, sarcin, and ricin toxins.24-27 The stability of 
these hairpin loops depend on the closing base pairs and the dangling end regions.28 The 
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dangling end is a non-helical structure present at the junction of double and single-stranded 
RNA.  
Thermodynamic studies investigating stabilization of duplex RNA structures by dangling 
ends have shown that 3’-dangling end have a larger stabilizing effect on RNA than 5’-dangling 
ends.29-34 Dangling ends also play important roles in biological functions other than stabilizing 
the RNA structures. For example, the dangling nucleotides (5’ACCA3’) present at 3’-terminal 
end of tRNA stabilize the cloverleaf structure of tRNA and the interaction between mRNA and 
tRNA adjacent to the codon-anticodon pair.35 Recent studies showed that 2-3 nt dangling ends 
are important in RNAi functionality.36-39 In our previous studies, we used virtual screening of the 
NCI diversity database to identify a small organic molecule QD1 that selectively recognizes a 3’-
dangling end of a RNA hairpin.40 Here, we report studies of QD1 binding to tetraloops by ITC 
(Isothermal Titration Calorimetry), identification QD2 by virtual screening of the entire NCI 
database (250,000 compounds) for QD1 like molecules, and QD2 binding cooperatively to a 
RNA hairpin containing a dangling end.  
2.2 Results and discussion 
2.2.1 Selective recognition of the 3’-dangling end of a hairpin by QD1 
Dr. Zhaohui Yan, a previous lab member of the Baranger Group, screened the NCI 
diversity set of 1990 compounds to identify small molecules that bind to RNA tetraloops. This 
screening identified a set of quinoline and acridine derivatives that bind to RNA tetraloops. The 
binding of an aminoacridine derivative (AD1), (AD2), and quinoline derivative QD1 to GNRA 
RNA tetraloops was characterized.40-42 The structure of GNRA tetraloops was previously solved 
by NMR spectroscopy and the NMR and secondary structure are shown in Figure 2-1.43 Dr. Yan 
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performed NMR diffusion experiments to determine the binding affinity of QD1 to RNA 
hairpins containing varied closing base pair and dangling end sequences. I confirmed the NMR 
experimental results using ITC (Isothermal Titration Calorimetry). The results of these 
experiments suggested that QD1 recognizes the RNA tetraloop on the basis of the terminal base 
pair and dangling end (Figure 2-2).  
 
 
 
 
 
Figure 2-1. NMR structure of the GCAA tetraloop (PDB code: 1ZIH)30 and the secondary 
structure of the tetraloop. 
 
 
 
                                   
 
 
 
Figure 2-2. QD1 recognizes the shaded region shown in the GCAA tetraloop. 
2.2.2 Isothermal titration calorimetry assays 
The recognition of three different RNA hairpins (Figure 2-3) by QD1 was studied using 
an isothermal titration calorimetry assay. The results were compared to the NMR diffusion 
experimental results. The advantage of ITC is there is no need to label the macro molecule, the 
  
interaction can be determined directly by measuring heat evolved or absorbed due to binding in 
solution, and the thermodynamic parameters for different binding events can also be determined. 
The data were fit using a sequential two-site binding model (Figure 2-4). The first binding 
constant values were within error of those determined by NMR diffusion methods. The second 
binding constant values were more than ten fold larger than the first and may result from 
aggregation of QD1, which we observed at higher concentrations in the NMR experiments 
(Table 2-1).  
 
 
 
 
 
Figure 2-3. Secondary structures of RNA hairpins used for experimental studies. 
 
 
 
 
 
 
 
 
 
Fgure 2-4. 
AU(UAU)    CG(UAU)   GU(UAU) 
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ITC profiles for the binding of QD1 to (a) AU(UAU) (b) CG(UAU) 
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Figure 2-4 (Cont.) 
 
 
 
 
 
 
 
 
 
 
Figure 2-4. ITC profiles for the binding of QD1 to (c) GU(UAU) RNA hairpins. Plots of data 
are from a representative ITC experiment upon titration of 50 µM of each RNA hairpin with 
QD1 (5 mM) in 10 mM sodium phosphate buffer (pH 6, 50 mM NaCl). The heat of ligand 
binding for each injection was determined by subtracting the heat of ligand solvation from that of 
the ligand-RNA injection to yield the heat due solely to ligand binding for each injection. 
Binding constants were determined from plots of the heat of ligand binding as a function of 
RNA-ligand molar ratio. The data were fit with a sequential two-site binding model. 
 
Table 2-1. Comparison of binding constants from NMR and ITC experiments. 
 
 
 
 
 
 
 
2.2.3 Virtual screening of the NCI database 
To identify molecules related to QD1 (Figure 2-6) that bind RNA tetraloops, we 
performed a computational substructure and/or 3D search of the NCI database of 250,000 
compounds. Out of the first 250 quinoline hits, forty molecules containing a quinoline 
(c) 
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substructure with a molecular weight of more than 200 and having different chemical scaffolds 
were selected. Of these forty molecules, 20 were selected for computational docking using MOE 
based on predicted water solubility and molecular weight.44 The program AutoDock 3 was used 
to perform computational docking of these 20 molecules with the GNRA tetraloop shown in 
Figure 2-1. The steps followed for screening the NCI database are shown in Figure 2-5. 
AutoDock has been validated by several investigators as an effective tool to identify small 
molecule ligands for RNA.45-47 This program uses a scoring function that includes van der 
Waals, electrostatic, desolvation, hydrogen bonding, and ligand torsional energies.48 We have 
previously used AutoDock in combination with Dock to identify ligands for the GNRA tetraloop 
and stem loop 3 of the Ψ RNA of HIV.41-42, 49 The docking site was defined using the AutoGrid 
program with a grid box of 40.0 Å X 30.0 Å X 34.0 Å (x,y,z) centered at 3.429 Å (x), -2.135Å 
(y) and 5.836Å (z). The ten quinoline derivatives with a predicted binding energy of better than -
9 kcal/mol were selected for experimental studies.  
The selected 10 quinoline derivatives were obtained from the NCI, and their purity was 
evaluated using NMR and mass spectrometry. The NMR and mass spectra of two of the 10 
molecules were not consistent with the reported structure and thus, were not investigated further. 
The structures of the small molecules studied experimentally are shown in Figure 2-6. The 
compounds high-lighted in red were not identified by NMR and mass spectrometry. The 
affinities of the remaining 8 molecules for GCAA RNA were determined using fluorescence 
spectroscopy. 
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Figure 2-5. Flowchart representing the steps followed in screening of NCI database. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 2-6. List of compounds from NCI studied experimentally. The compounds high-lighted 
in red were not identified by NMR and mass spectrometry. The one shown in blue was the best 
hit and was evaluated further (QD2). 
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2.2.4 Screening of molecules by fluorescence assays 
The binding affinity of selected molecules for the GCAA tetraloop was measured by 
fluorescence titration experiments. The sequence of the GNRA tetraloop used in these 
experiments is shown in Figure 2-7. The change in the fluorescence signal was measured upon 
titration of 5’-fluorescein-labeled GCAA tetraloop RNA with increasing concentration of small 
molecule. A control experiment has been done for each experiment by titrating fluorescein with 
small molecule to make sure that the small molecules are not interfering with the fluorescein 
flurophore. None of the molecules altered the fluorescence signal of fluorescein in control 
experiments. The molecule NSC5920 precipitated above 10 µM, and NSC3618 showed 
fluctuations in the fluorescence signal. As a result, the approximate binding constants of these 
two molecules for tGCAA RNA were not determined. The summary of fluorescence screening 
results was shown in Table 2-2. Interestingly, one of the six molecules, NSC5485 (QD2) was 
found to bind with better affinity than QD1. 
Table 2-2. Summary of fluorescence screening assay results. 
  
 
 
 
  
 
 
The AutoDock results for all the molecules shown above have almost similar binding 
energy but only QD2 was found to bind better than other molecules. The QD2 binding curve has 
NCI 
compounds 
Fluorescence 
KD ( µM) 
NSC3618 Fluctuations in 
fluorescence intensity 
NSC3870 > 100 µM 
NSC 3616 > 90 µM 
NSC2455 > 150 µM 
NSC5920 Start precipitating at 10 
µM 
NSC1010 > 60 µM 
NSC5491 > 50 µM 
NSC5485 8 µM 
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‘S’ shape and was not fit properly with one or two binding site model. The QD2 was further 
evaluated for its high binding affinity and the shape of the binding curve. The compound is less 
soluble in water-DMSO (75 µM in 3.5% v/v DMSO) and the maximum concentration of 50 µM 
in 3.5% v/v DMSO used for our experimental studies. The effect of DMSO alone and with QD2 
on the fluorescence signal is shown in Figure 2-7. DMSO increased the fluorescein signal 
whereas, the QD2 in DMSO quenched the signal. The results indicate that DMSO did not 
contribute to the quenching of the fluorescein signal upon addition of QD2.  
 
 
 
 
 
 
 
 
Figure 2-7. (a) Titration of 5’ fluorescein labeled RNA (100 nM) with inc
DMSO alone (red) and QD2 (NSC5485) in DMSO (blue). (b) The seque
tetraloop (FL-GCAA) used for the fluorescence experiments. 
 
The typical fluorescence quenching spectrum with increasing conce
shown in Figure 2-8. The binding curves obtained looks like ‘S’ shaped curv
binding curves are usually obtained due to cooperative interactions between s
the presence of identical interacting sites. The experimental data were fit w
determine association constant. The binding curve (Figure 2-9) was fit w
equation, supporting the interaction of four small molecules with one RNA tar
(F-F0)/(Ff-F0) = (KL4)/(1+ KL4)           (1) 
FL-tG
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F is the fluorescence intensity of the sample, F0 is the initial fluorescence intensity, Ff is the final 
fluorescence intensity, K is the association constant and L is the ligand concentration. A 
dissociation constant of 8.2 ± 0.4 µM for the complex formed between QD2 and the GCAA 
tetraloop was obtained from an average of three titrations.  
  
 
 
 
 
 
 
Figure 2-8. Fluorescence spectra for 5’-fluorescien labeled GCAA RNA titrated with increasing 
concentrations of QD2. Measurements were performed with an RNA concentration of 100 nM 
and QD2 concentrations ranging from 0 to 21 µM in 10 mM sodium phosphate buffer (pH=6, 50 
mM NaCl). The intensity of the fluorescence signal of fluorescein decreased upon addition of 
QD2. 
 
 
 
 
 
 
Figure 2-9. Plots for the fraction of RNA fluorescence signal quenched versus QD2 
concentrations in the absence (left) and presence (right) of 0.01% Triton X-100 assuming a 1:4 
binding stoichiometry. The fraction of RNA bound was calculated using the fluorescence 
emission at 520 nm by excitation at 490 nm. The data were fit to equation 1. The experiments 
were performed with 100 nM GCAA RNA and 0 to 34 µM QD2 in 10 mM sodium phosphate 
buffer (pH=6, 50 mM NaCl). 
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False positive hits from computational docking may arise for compounds that aggregate 
because the aggregates can be responsible for the observed binding rather than the isolated 
molecules.50-51 Because QD2 is sparingly soluble in water-DMSO (75 µM in 3.5% v/v DMSO) 
mixture, we performed experiments in 0.01% Triton X-100 in order to confirm that the binding 
seen was not due to aggregates. The effect of Triton X-100 on the aggregation of small 
molecules has been studied by Shoiket and co-workers.51 Concentrations of 0.01% are typically 
sufficient to prevent the aggregation. The dissociation constant obtained in presence of Triton X-
100 is 12 ± 0.5 µM which is similar to the measured binding constant in the absence of Triton X-
100. These results suggest that aggregates of QD2 are not responsible for the observed binding. 
The binding curve in the presence and absence of 0.01% Triton-X 100 is shown in Figure 2-9. 
2.2.5 Stoichiometry of binding 
       The unusual stoichiometry of binding was further investigated using a fluorescence assay.  
Because the compound precipitates at higher concentrations, reverse titration was used to 
determine the stoichiometry of the complex formed between QD2 and the GCAA tetraloop. For 
these experiments, the QD2 concentration must be significantly above the KD. Therefore, these 
experiments were done with 25 µM concentration of QD2, which is 3-fold to the dissociation 
constant of QD2 to GCAA RNA tetraloop. The stoichiometry was determined by adding 
increasing concentrations of GCAA tetraloop to a constant concentration of QD2 (25 µM in 
4.6% v/v DMSO in 10 mM sodium phosphate buffer, pH=6). The stoichiometry of binding was 
found to be 1:4, and an example of a stoichiometry experiment is shown in Figure 2-10. The 
results obtained correlate with the number of binding sites determined from the fluorescence 
binding experiment.   
 
  
32
 
 
 
 
 
 
 
 
Figure 2-10. A plot of the fraction of RNA bound vs molar ratio ([RNA]/[ligand]) that was used 
to determine the stoichiometry of the QD2-GCAA RNA complex. The QD2 (25 µM in 3.5% v/v 
DMSO) was titrated with GCAA RNA in 10 mM sodium phosphate buffer (pH=6, 50 mM 
NaCl). The excitation and emission wavelengths were 310 nm and 369 nm, respectively. 
 
2.2.6 Isothermal titration calorimetry experiment 
To confirm the binding constants and the stoichiometry of binding, experiments were 
performed using isothermal titration calorimetry (ITC). The binding constants were obtained by 
doing a reverse titration where the ligand was titrated with the GCAA RNA tetraloop. An 
example of the ITC experiments is shown in Figure 2-11. The binding curve obtained was fit 
with a sequential four site binding model. The comparison of the binding constants obtained 
from ITC and the fluorescence binding assay is shown in Table 2-3. The data obtained using ITC 
are consistent with the fluorescence data and support the presence of four identical interacting 
sites. Cooperativity is a common phenomenon in which two or more otherwise independent 
processes are thermodynamically coupled and generally involves a change in the molecular 
conformation of molecules.52 The absence of biphasicity in the binding curve of interaction 
indicates cooperativity between the four ligand binding sites, although it is not apparent from the 
calorimetric data alone.53-54  
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Figure 2-11. Plots of data from a reverse titration ITC experiment. QD2 (20 µM in 3.5% v/v 
DMSO) in 10 mM sodium phosphate buffer (pH=6, 50 mM NaCl) was titrated with increasing 
concentrations of 200 µM RNA at 25 0C. A standard experiment consisted of titrating 20 µM of 
QD2 (1.42 mL in sample cell) with 10 µL of 200 µM of RNA solution. A control experiment 
was performed that involved addition of aliquots (10 µL) of QD2 (20 µM) into buffer alone. The 
heat of ligand binding for each injection was determined by subtracting the heat of ligand 
solvation from that of the ligand-RNA injection to yield the heat due solely to ligand binding for 
each injection. Binding constants were determined from plots of heat of ligand binding as a 
function of RNA-ligand molar ratio. The data was fit with a sequential four-site binding model. 
 
Table 2-3. Comparison of binding constants for the binding of QD2 with RNA hairpin from 
fluorescence and ITC experiments.  
Binding 
Constants  (µM) 
Fluorescence Fluorescence 
(0.01% Triton) 
ITC 
 
K1 8.2 ± 0.4 12.0 ± 0.5 10.8 ± 1.2 
K2 8.2 ± 0.4 12.0 ± 0.5 9.2  ± 2.4 
K3 8.2 ± 0.4 12.0 ± 0.5 8.1  ± 1.8 
K4 8.2 ± 0.4 12.0 ± 0.5 12.5  ± 4.2 
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2.2.7 CD spectroscopy 
A conformational change in the GCAA tetraloop was expected upon binding to four QD2 
ligands and was confirmed by CD spectroscopy. These experiments were performed by titrating 
the GCAA tetraloop with QD2, and monitoring the CD spectrum from 240 nm to 320 nm. The 
DMSO present in the ligand buffer interferes with the signal below 240 nm. As shown in Figure 
2-12, there is large change in the conformation of the tetraloop upon binding to ligand. The 
change in conformation makes the GCAA tetraloop bind to four ligands by creating new binding 
sites.  
 
 
 
 
 
 
Figure 2-12. Circular dichroism spectra of GCAA (15 µM in 400 µL of buffer) titrated with 
increasing concentrations of QD2 (7.5 µM to 50 µM in 3.5% v/v DMSO). GCAA RNA alone is 
shown in pink in 10 mM sodium phosphate buffer (pH=6, 50 mM NaCl).  
 
2.2.8 UV reverse titration experiment 
In UV titration experiment changes in the λmax of chromophore of the system is observed 
when there is binding between nucleic acid and small molecule. Because the DMSO interferes 
with the absorption of RNA, a reverse titration was performed. QD2 (20 µM) in buffer (1.65% 
v/v DMSO) was titrated with increasing concentrations of RNA (6.4 µM to 54 µM). The UV 
reverse titration experiments indicated the displacement of maximum absorption of QD2 from 
329 nm to 335 nm (bathochromic shift of 6 nm) and a large hypochromism of 48.1% (0.316 to 
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0.152). The large hypochromism was observed due to perturbation of the complexed 
chromophore system up on binding to RNA. The titration experiment is shown in Figure 2-13.  
 
 
 
 
 
 
 
Figure 2-13. The UV reverse titration experiment. QD2 (20 µM, purple) in 10 mM sodium 
phosphate buffer (pH=6, 50 mM NaCl), (1.65% v/v DMSO) was titrated with increasing 
concentrations of RNA (6.4 µM to 54 µM). 
 
2.2.9 Binding specificity of QD2 molecule 
 The binding specificity of the QD2 was investigated by studying its binding to single 
stranded, duplex, GCAA tetraloop and SL2 RNAs. Stem loop 2 RNA has a stable loop structure 
binds to a component of spliceosomal protein called U1A and GCAA tetraloop is without the 
dangling end sequence UAU present in the GCAA tetraloop RNA. The sequences of RNAs used 
for the experiment are shown in Figure 2-14. The binding studies were performed by 
fluorescence assay with 5’-fluorescein labeled RNAs. Stem loop 2 RNA was selected to study 
the specificity of QD2 to different loops and tetraloop RNA was selected to check the binding 
affinity without dangling end. The dissociation constant of the QD2 molecule with these RNAs 
did not differ much compared to the actual target (Table 2-4). These results suggest that the 
compound QD2 does not bind RNA specifically and its affinity for single stranded RNA is 
higher than for duplex RNA. 
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Figure 2-14. The sequences of RNA used for the specificity assessment studies by fluorescence 
assays. All the RNA sequences were labeled with fluorescein at the 5’-end. 
 
Table 2-4. The equilibrium dissociation constants for QD2 binding to different RNA targets. 
 
 
 
 
 
2.3 Conclusion 
The results indicate the unusual 1:4 stoichiometry of binding between the GCAA 
tetraloop and QD2 (NSC5485). The binding of dimerized molecules cooperatively to RNA may 
be the reason for this unusual stoichiometry. The compound is not specific for the GCAA 
tetraloop and binds with higher affinity to single stranded RNA than to other RNA structures. 
The interaction between molecules is probably governed by stacking and both stacking and 
electrostatic interactions with GCAA tetraloop. The cooperativity might be the reason for the 
greater affinity of QD2 with GCAA tetraloop compared other screened molecules.  All the four 
binding sites are identical and there is cooperativity between the molecules binding.  
RNA With out Triton 
X-100  (µM) 
With Triton X-100            
(0.01% v/v)  (µM) 
Single strand 4.15 ± 0.2 10.3 ± 0.49 
FL-tGCAA 8.2 ± 0.4 12.0 ± 0.5 
GCAA 7.5 ± 0.7 16.6 ± 0.29 
Duplex 6.4 ± 0.4 18.3 ± 1.2 
SL2 9.2 ± 0.2  
  
37
2.4 Experimental section 
2.4.1 Computational studies using AutoDock 
Computational work was performed on a Silicon Graphics Origin 200 with a CPU of 4 X 
R10000 @ 180 MHz, 512 MB RAM, and an Irix 6.5.5 operating system. AutoDock 3.0 was 
obtained free of charge from Molecular Graphics Laboratory of the Scripps Research Institute. 
MOE (Molecular Operating Environment) was used to add hydrogens and partial charges to the 
RNA and small molecules. 
The GCAA tetraloop NMR solution structure was obtained from the PDB (Brookhaven 
Protein data bank). The PDB code for the GCAA tetraloop is 1ZIH. Amber 94 force field was 
used to charge RNA and GESTAGER PEOE was used for charging small molecules. The 
docking energy obtained with AutoDock 3 was compared to the QD1 docking energy. 
Compounds which had a binding energy less than the predicted for QD1 were eliminated and the 
rest were used in experimental studies.  
2.4.2 Materials and methods 
All the compounds tested were obtained from the Drug Synthesis and Chemistry Branch, 
Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National 
Cancer Institute (Bethesda, MD). The identity of the compounds was studied by NMR and mass 
spectrometry. RNA sequences were purchased either PAGE purified or crude from Dharmacon 
Research Inc. (Lafayette, CO). The PAGE purified RNA sequences were deprotected using the 
volatile deprotecting buffer provided and were lyophilized following the procedures provided by 
Dharmacon. The crude RNA sequences were first deprotected and then purified by 20% denaturing 
polyacrylamide gel electrophoresis. The RNA bands were visualized by UV and excised from 
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the gel. RNA was extracted from the gel by TE (1M Tris-Cl, 0.5 M EDTA, pH=7.5) extraction. 
The RNA was dialyzed against water and desalted by two ethanol precipitations and then 
lyophilized. The purity and identity of RNA samples were confirmed using MALDI mass 
spectrometry. The RNA samples were annealed by heating to 95 0C for 2 min followed by 
cooling on ice for 5 min immediately before all the experimental studies. 
2.4.3 RNA purification by denaturing PAGE 
A 20% polyacrylamide denaturing gel was prepared by mixing Sequa gel concentrate (60 
mL), Sequa gel dilute (7.5 mL), and Sequa gel buffer (7.5 mL) from National Diagnostics. The 5 
mL gel mixture was used to make the plug and before pouring the plug into the space between 
the glass plates, the solution was mixed with 20 µL APS (ammonium persulfate) and 10 µL 
TEMED (tetramethylethylenediamine, Aldrich). After the polymerization of the plug, 210 µL 
APS and 105 µL TEMED were added to the remaining 70 mL of gel mixture, mixed, and poured 
constantly until the entire plate was filled. An appropriate comb was inserted, and the gel was 
placed horizontally for an hour to allow the gel to polymerize before use. The 5X TBE running 
buffer was prepared by adding Tris base (54 g), Boric acid (27.5 g), EDTA (3.72 g) in 1 L 
autoclaved water. The 1X TBE buffer was prepared from the 5X TBE and used for running the 
gel. Formamide loading buffer was prepared by mixing, formamide (9.8 mL, Aldrich), EDTA 
(0.5 M, 200 µL, pH 8.0), Bromophenol blue (10 mg), and xylene cyanol (10 mg). The comb was 
removed from the polymerized gel, the gel was pre-run for 30 minutes at 45 watts. The bubbles 
and urea were removed form the wells using a syringe before loading the samples.  
The RNA sample (50 µL) was mixed with the formamide loading buffer (100 µL), and 
heated at 95 0C for 2 min, rapidly cooled on ice, and then loaded in to the wells. After running 
the gel at 45 watts for 3 hours, the glass plates were carefully removed. The gel was covered with 
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a clean sterile plastic wrap and placed on top of a TLC plate. The RNA band was visualized 
using an UV lamp (at 254 nm), was isolated using a sterile razor, and placed in to a 2 mL 
eppendorf tube. The excised RNA band was kept on dry ice for 15 min and then crushed with a 
sterile pipette. TE buffer (1 mL) was added to the tube, and the tube was left to shake slowly at 4 
0C for 6 hrs. The supernatant containing the RNA was collected and saved. The extraction 
procedure was repeated three times to make sure that all RNA was recovered. The combined 
supernatant was dialyzed using MWCO 1000 membrane against 10X diluted TE (2 mL of 1 M 
Tris (pH 7.4) and 400 µL of 0.5 M EDTA (pH 8.0) diluted with autoclaved water) three times 
within a period of 24 hrs. The dialyzed RNA sample was dried using a speed-vac and was 
ethanol precipitated twice. The concentration was determined by UV spectrophotometer.  
Ethanol precipitation 
The RNA sample was dissolved in 50 µL TE buffer (10 mM Tris pH 7.4, 1 mM EDTA), 
2 µL of 5 M NaCl solution was added to achieve a final NaCl concentration of 200 mM, and 
three times the volume of chilled ethanol (150 µL) was added. The solution was vortexed, chilled 
on dry ice for 15 min, and centrifuged at 14,000 rpm at 4 0C. The supernatant was removed, 
leaving the RNA sample in the tube.  
2.4.4 Fluorescence experiments 
FluoroMax-3 Spex spectrofluorometer from Jobin Yvon Inc. was used for fluorescence 
experiments. The RNA labeled with fluorescein at the 5’-end and QD2 dissolved in 100% 
DMSO were used for experiments. The RNA was titrated with QD2 and the change in 
fluorescence intensity of RNA was observed. The RNA was excited at 510 nm, and emission 
scans were obtained from 510 to 530 nm with an excitation slit width of 2 nm and an emission 
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slit width of 5 nm. The buffer intensity and background fluorescence was subtracted for each 
titration and an average of 5 scans were obtained. The fraction of RNA bound was calculated 
using the emission at 520 nm by dividing the difference between the observed fluorescence F 
and the initial fluorescence F0 by the difference between final fluorescence Ff and initial 
fluorescence as shown in equation 1. A control experiment in which DMSO alone was titrated in 
to the RNA sample was performed and these intensities for subtracted from the actual 
experiments. The fluorescence experiments were also performed in presence of 0.01% v/v Triton 
X-100 to observe the effect of aggregation of small molecule on fluorescence signal. 
The stoichiometry of the complex formed between QD2 and the GCAA tetraloop was 
determined by reverse titration. The QD2 was excited at 310 nm, and emission scans were 
obtained from 355 to 390 nm with an excitation slit width of 5 nm and an emission slit width of 5 
nm. The maximum emission was observed at 369 nm. The plots of fraction bound vs the molar 
ratio ([RNA]/[ligand]) was used to find the stoichiometry. 
2.4.5 Isothermal titration calorimetry experiments 
ITC experiments were performed at 25 0C on a MicroCal VP-ITC (MicroCal, Inc., 
Northampton, MA). The experiments were performed in 3.5% v/v DMSO in sodium phosphate 
buffer by reverse titration. A standard experiment consisted of titrating 20 µM of QD2 (1.42 mL 
in sample cell) with 10 µL of 200 µM of RNA solution in a syringe. The standard experiment 
was accompanied by a corresponding control experiment in which aliquots (10 µL) of QD2 (20 
µM) were titrated into buffer (10 mM sodium phosphate pH=6) alone. The duration of each 
injection was 24 s, and the spacing between two injections was 240 s. The initial delay prior to 
the first injection was 60 s. The instrument measured the heat released for each injection in 
µcal/sec. The heat associated with each injection was measured by determining the area under 
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the curve using Origin version 5.0 software (Microcal, Inc., Northampton, MA, USA). The heat 
of ligand binding for each injection was determined by subtracting ligand solvation (Buffer 
titrated with ligand) from the corresponding heat associated with ligand-RNA injection to yield 
the heat due solely to ligand binding for each injection. Binding constants were determined from 
plots of heat of ligand binding as a function of ligand-RNA molar ratio. The graph was fit using 
a sequential four-site binding model. 
2.4.6 CD spectroscopy 
CD experiments were carried out using a JASCO 715 spectropolarimeter. The spectra 
were recorded from 200 to 320 nm region. The RNA (15 µM of 400 µL in 10 mM sodium 
phosphate pH=6, 5 mM NaCl buffer) titrated with increasing concentrations of QD2 (7.5 µM to 
50 µM) in 3.5% v/v DMSO. At least two spectral scans were obtained at a temperature of 25 0C 
in a 0.5 cm path length cell at a scan rate of 10 nm/min. 
2.4.7 UV reverse titration experiments 
UV titration experiments were performed using a Shimadzu UV-2450 spectrophotometer. 
Reverse titration experiments were recorded from 320 to 350 nm region. The QD2 has maximum 
absorption at 329 nm. The QD2 (20 µM) in 10 mM sodium phosphate pH=6, 50 mM NaCl 
buffer (1.65% v/v DMSO) was titrated with increasing concentrations of RNA (6.4 µM to 54 
µM). 
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CHAPTER 3 
Unraveling the Interaction of Poly(CUG)RNA with the MBNL1 
Protein 
3. 1 Significance of RNA-protein interactions 
RNA-protein interactions are important in biological events that perform multiple 
functions in all living organisms. RNA often serves as a mediator of genetic information between 
DNA and protein in eukaryotes and prokaryotes. In addition, RNA serves as the genetic material 
in some viruses. Based on the function or localization RNAs are classified into transfer RNA 
(tRNA), messenger RNA (mRNA), ribosomal RNA (rRNA), viral RNA (vRNA), small nuclear 
RNA (snRNA) and small cytoplasmic RNA (scRNA). These RNA form complexes with a wide 
variety of RNA-binding proteins that stabilize, protect, package, or transport RNA, mediate RNA 
interactions with other macromolecules, and also act catalytically on RNA (cutting, unwinding, 
modifying, replicating etc.).1 The fundamental roles of RNAs and RNPs (ribonuclear protein 
complexes) are shown in the following diagram (Figure 3-1).2 The modulation of RNA-protein 
or RNA-RNA interactions involved in transcription, mRNA processing, protein translation, or 
retroviral gene expression could provide new drugs to treat cancer, combat bacterial and viral 
infections. Targeting RNAs and RNPs with small molecules could also induce effects which are 
not achievable through targeting proteins. Interestingly, many of the currently available drug 
targets are membrane bound receptors3-4 and it is difficult to study these proteins using standard 
techniques and equally challenging to integrate into high-throughput screens. So the effect of 
small molecule on the receptor cannot be assayed or quantified easily. In such a case, the 
modulation of mRNA transcript that codes for the receptor could be alternative way for finding 
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an effective treatment. The development in the fields of structural studies of RNA-protein 
complexes and their biological functions, RNAs and RNA-protein complexes are becoming 
increasingly attractive targets for drug design. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1. Representation of the diverse fundamental roles of RNAs and RNPs in the 
maintenance and transfer of biological information from DNA to protein. RNAs and RNP 
involved in DNA replication (chromosome maintenance and DNA synthesis); transcriptional 
control (mRNA processing); protein translation; and retroviral reverse transcription, gene 
expression and packaging. All these important process controlled by RNA and RNPs make them 
potential drug targets for the development of new drugs. 
 
 
3. 2 RNA-protein recognition 
Most functions of RNA require interactions with RNA-binding proteins. The knowledge 
of RNA-protein recognition is informative for designing small molecules targeting RNA. 
Because, proteins may use similar strategies for binding to RNA and protein-binding sites are 
potential targets for drug action. A prominent example of recognition of the same region in RNA 
by a protein and a small molecule is binding of the viral Rev protein as well as neomycin B 
binding to a non-Watson-Crick G-G base pair with in the HIV-RRE RNA.5-6  
Most RNAs occur as partially folded single-stranded molecules. The A form helix of 
RNA has a narrow deep major groove, which buries the edges of the base and the readily 
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accessible shallow minor groove contains less information for recognition.7 The distortions in 
regular A form helix by non-Watson-Crick base pairs forms looped out residues and platforms of 
consecutive nucleotides with widened deep groove.1, 8-9 Proteins not only recognize but may also 
enhance such distortions of RNA structure.  Insertion of an α-helix or a flexible protein loop into 
a widened deep groove has been observed in several protein-RNA complexes.8, 10 Exposed β-
strands of proteins can interact with unpaired RNA regions by stacking the splayed-out bases 
with aromatic amino acid side chains.1, 11 Flexible protein loops participate predominantly in 
interactions with the RNA backbone, often leading to reduced loop flexibility.1, 10 There are 
remarkable differences between RNA-protein and RNA-peptide complexes.12-13 In RNA-protein 
complexes the large proteins predominantly bind RNAs as rigidly folded domains which provide 
exposed surfaces, cavities, clefts for the RNA substrate, where as in RNA-peptide complexes, 
these changes are observed very frequently.  
The negatively charged phosphate backbone of RNA interacts with protein side chains 
through hydrogen bonding, which is seen in 90% of RNA-protein complexes.14 In complexes of 
known structure, 20% of intermolecular interactions involve the 2’-OH group equally often as a 
hydrogen bond donor and acceptor. The basic amino acids arginine and lysine participate in 60% 
of intermolecular H-bonds and the flat guanidinium side chain of arginine forms stacking 
interactions with RNA.14 The stacking interactions involve both RNA and protein residues in 
alternating fashion, often called interdigitation,8 and the hydrophobic parts of RNA bases align 
with the nonpolar side chains of proteins. The positions 6 and 7 of purine and position 4 of 
pyrimidine form hydrogen bonds with proteins. The RNA folds created due to non-Watson-Crick 
base pairing also provide excellent recognition sites for proteins.15 Water and ions also play 
important roles in maintaining the three dimensional structure of RNA-protein complexes. Water 
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molecules are often found at the binding interfaces where they extend shape complementarity by 
filling cavities. 
3. 3 RNA binding proteins in human diseases  
RNA-binding proteins are widely involved in the posttranscriptional processing of RNAs, 
play key roles in exon-intron splicing, nuclear export, polyadenylation, subcellular localization, 
translationlcontrol, stabilization/degradation and sequence editing.16 In particular, the expression 
of RNA-binding proteins restricted to specific cell types perform important functions by 
controlling the subcellular distribution of proteins, levels of proteins, the production of certain 
protein isoforms and therefore, confer distinct phenotypes to cells. The perturbation of normal 
functions of RNA-binding proteins has been implicated in many clinical disorders. RNA-binding 
proteins implicated in diseases include the CELF proteins (e.g., CUG-BP), which are believed to 
play roles in normal heart and skeletal muscles development and in the pathology of myotonic 
dystrophy, the Nova autoimmune antigens, which are neuron-specific proteins involved in the 
pathogenesis of the neurodegenerative syndrome paraneoplastic opsoclonus-myoclonus ataxia 
(POMA), and the αCP proteins, which have been suggested to cause α-thalassemia.17 The 
mechanism by which these proteins control the expression of proteins in their respective cell 
types is still unknown. The investigation of relationship between the structure and function of 
these proteins will begin to reveal how they help to shape the protein expression programs 
unique to skeletal muscle, heart, brain and other tissues.  
3. 4 RNA dominant diseases 
The fraction of the human genome transcribed far exceeds the fraction that encodes 
protein.18 Mutations in non-protein-coding regions give rise to deleterious gain-of-function by 
non-coding RNA similar to the function of mutated proteins. This RNA gain of function often 
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involves repetitive sequences in non-coding RNA. The repetitive sequences in non coding 
regions causes various diseases including, myotonic dystrophy, fragile X tremor ataxia syndrome 
(FXTAS), spinocerebellar ataxia type 8 (SCA8), SCA10, SCA12, and Huntington's disease-like 
2 (HDL2) (Figure 3-2).19 In 1991, the first two triplet repeat expansion disorders discovered 
revealed mutations in coding and non-coding regions. The unstable CGG repeat expansion in the 
noncoding 5’UTR (untranslated region) of FMR1 causes fragile X syndrome20-21 whereas 
spinobulbular muscular atrophy is associated with unstable CAG repeat expansions in the coding 
region of AR (androgen receptor) gene.22 Later, in 1992, a third trinucleotide repeat disorder was 
discovered, which is caused by a CTG repeat expansion in the noncoding 3’UTR of DMPK 
(Dystrophyia Myotonica Protein Kinase) gene.23-27 The noncoding triplet repeat expansion 
diseases SCA8 and Friedreich ataxia are caused by tandem CTG and GAA repeat units, 
respectively.28-29 SCA8 was the first disease predicted to be caused by a noncoding RNA repeat 
sequence but studies on myotonic dystrophy unveiled the critical role of RNA in contributing to 
disease phenotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2. Schematic diagram showing the position and relative sizes of disease associated 
microsatellite repeat expansions located in the non-coding regions of respective genes. The black  
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line (left) represents promoter and intron (right); blue boxes represent 5’ and 3’ untranslated 
regions; solid red boxes protein coding regions.   
 
3. 5 Myotonic dystrophies 
 
Steinert and Batten (1909) identified myotonic dystrophy as a multisystemic disorder that 
is now recognized as one of the most common forms of muscular dystrophy in adults.30 The 
geneticists and clinical neurologists identified non-Mendelian features of myotonic dystrophy 
inheritance, including variable penetrance, anticipation (a tendency for the disease to worsen in 
subsequent generations), and a maternal bias transmission for congenital forms.31 In 1992, the 
generic cause for the disease was identified as the expansion of an unstable CTG-repeat in the 3’-
ntranslated region of a gene encoding DMPK gene23-27 and the disease was called as myotonic 
dystrophy type 1 (DM1). In 1995, several reports described families with dominantly inherited 
multisystemic myotonic disorders that were genetically distinct from DM1,32-34 and later in 1998 
a CCTG-repeat expansion in intron 1 of ZNF9 (zinc finger protein 9) gene was identified as the 
cause of the disease and referred to as a second form of myotonic dystrophy (DM2). DM2 
disease has also been called as proximal myotonic myopathy (PROMM) or proximal myotonic 
dystrophy. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-3. Schematic illustration of the location of DM1 and DM2 gene loci and the insertion 
of (CUG)n and (CCUG)n A form of duplex RNA from (CTG)n and (CCTG)n DNA repeats, 
respectively. 
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3. 6 Molecular genetics of DM1 and DM2 
DM1 is more common than DM2, accounts for approximately 98% of DM cases, and 
affects 1 in 8000 people worldwide.31 The symptoms of the disease are similar for DM1 and 
DM2. However a key difference between DM1 and DM2 is that only the DM1 locus presents a 
congenital form of this disorder but not in DM2.  The DMPK gene located on chromosome 
19q13.3 and ZNF9 is on chromosome 3q21 (Figure 3-3). In DM1 the CTG expansions vary from 
50 to 4,000 repeats in affected patients, with clinically unaffected patients having up to 50 CTGs. 
Whereas in DM2 the CCTG expansion in pathological condition is around 75 to 11,000 repeats. 
Somatic instability has been reported in different patients and the elongation in DM1 and DM2 
are 50 to 80 and 700 repeats per year, respectively. There is a rough correlation between DM1 
repeat size and age of onset for CTGs < 400 but poor correlation between repeat length and 
disease severity for long repeats.35-36  
Table 3-1. Etiology of Myotonic dystrophies 
 
 
 
 
 
 
 
3. 7 Clinical features of the myotonic dystrophies 
Myotonic dystrophies (DMs) are autosomal dominant, multisystemic disorders with 
symptoms including myotonia (muscle hyperexcitability), progressive muscle weakness and 
wasting, cataract development, testicular atrophy and cardiac conduction defects.37 In the initial 
stages of DM1 and DM2 the pattern of muscle weakness is noticeably different (distal vs 
proximal) but the muscle biopsies show a similar histology with increased muscle fiber size and 
Type DM1 DM2 
Gene DMPK ZNF9 
Mechanism CTG repeat CCTG repeat 
Normal repeat size Up to 37 Up to 27 
Pathologic repeat size >50 CTG >75 CTG 
Expanded repeat range 50-4000 75->11000 
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central nucleation. The cataract usually develops in the second decade or later and is 
characterized by mutlicolored lens opacities and is the most easily treatable among all the 
symptoms caused by this disease. The other common symptoms are testicular atrophy, insulin 
insensitivity, frontal balding, hypogammaglobulinemia (reduced IgG and IgM serum levels), 
lethal arrhythmias and occasional sign of cardiomyopathy.36  
Clinical Features of Myotonic Dystrophy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4. Schematic representation of clinical features of myotonic dystrophy which are 
common in DM1, DM2 and specific for DM1 and DM2 types. 
 
                  The CCTG expansion repeat size in DM2 is longer than the CTG repeat in DM1 but 
the symptoms in DM2 are less severe than in DM1. Most of the clinical features of DM2 appear 
in adulthood (median age 48 years)38 as opposed to DM1 that clearly demonstrates adult-onset, 
childhood-onset and congenital forms with corresponding increasing disease severity and repeat 
size. The neonatal symptoms of congenital DM1 do not include some of the features 
characteristic of adult onset DM1 and DM2, such as cataract development, myotonia and 
myopathy.31Instead, congenital DM1 is associated with hypotonia, mental retardation, facial 
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diplegia and a maternal bias in DM transmission (Figure 3-4). Although there are a few reports 
of childhood-onset in DM2, they are not usually associated with a developmental disease of the 
central nervous system as in congenital and childhood-onset DM1. The patients who survive 
with congenital and childhood onset eventually manifest the hallmark features of adult-onset 
form of disorder. 
3. 8 RNA pathogenesis in myotonic dystrophy 
The current hypothesis of the molecular basis of DM1 and DM2 is that the unstable 
expanded repeats cause misregulation of pre-mRNA splicing. Three distinct models have been 
proposed to explain the molecular mechanisms of DM pathogenesis. (1) Haploinsufficiency of 
the DMPK gene, (2) Altered expression of neighboring gene, and (3) dominant-negative mRNA 
expression.36-37 The first two models have been shown to be wrong with mice knockout 
experiments. The third model promotes the hypothesis that dominant-negative pathogenic effects 
of RNA containing the CUG and CCUG expansions cause DM. The transcripts with CUG and 
CCUG expansion repeats accumulate as ribonuclear inclusions (RNA foci) in the nuclei of DM 
cells and are detectable by in situ hybridization.39-44 These poly(CUG)RNA and 
poly(CCUG)RNA alter the RNA binding activity of some proteins including the CUG-binding 
protein (-BP), CCUG-BP and three different forms of muscle blind like proteins (MBNL1, 
MBLL, and MBXL) (Figure 3-5). The CUG-BP is localized in both nucleus and cytoplasm and 
binds specifically to UG repeat sequences but not to ribonuclear foci. The levels of CUG-BP and 
CCUG-BP seem to be increased in several DM cells and the specific mechanism for up-
regulation is still not known. The muscleblind-like proteins colocalize with ploy(CUG)RNA and 
poly(CCUG)RNA in DM cells and are proposed to induce pathogenesis by at least  three 
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mechanisms: (1) misregulation of pre-mRNA splicing, (2) interference with muscle 
differentiation, (3) transcriptional interference.45 
Figure 3-5. The RNA gain-of-function model of myotonic dystrophy pathogenesis. The left side 
of the figure represents the free form of MBNL1 which performs its normal pre-mRNA splicing 
in a healthy individual. The right side of the figure represents the condition in the disease state. 
The expanded poly(CUG)RNA or poly(CCUG)RNA form an imperfect double stranded 
structure. This affects regulation of splicing by sequestering the important splicing regulator 
MBNL1 protein. 
 
3. 9 Misregulation of alternative splicing 
 
Alternative splicing is a process by which multiple mRNA isoforms are generated from 
individual genes. This gives rise to protein isoforms that significantly differ in their activity.46 
Alternative splicing involves the binding of regulatory factors to intronic or exonic elements and 
is regulated according to cell type or developmental stages. It has a huge impact on multiple 
aspects of cell and tissue physiology.47 Misregulation of alternative splicing has been implicated 
in many human diseases.47-48 Misregulated alternative splicing events have been identified in the 
heart, skeletal muscle, and central nervous system of DM1 patients and are summarized in Table 
3-2. This misregulation affects only a subset of genes, indicating that most genes are unaffected 
by DM1.49 Interestingly, all pre-mRNAs misregulated in DM1 normally undergo a 
developmentally regulated splicing switch. In DM1, the embryonic or fetal splicing patterns of 
these genes are retained in adult tissues. Misexpression of the early developmental isoforms for 
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IR and CLCN-1 has been shown to directly correlate with the disease symptoms such as insulin 
resistance and myotonia, respectively (Figure 3-6).50-53  
 
 
Figure 3-6. Misregulation of alternative splicing of IR and ClC1 pre-mRNAs in DM skeletal 
muscle. The fetal isoforms of IR and ClC1 predominates in adult tissues (shaded boxes). The 
fetal splicing pattern of IR pre-mRNA results in expression of a fetal isoform with exon-11 
exclusion having lower receptor activation. Whereas inCLC1 the exon 7a containing a premature 
termination codon inclusion results in nonsense-mediated decay (NMD) degradation.53  
 
The specific mechanism by which poly(CUG)RNA or poly(CCUG) RNA induces 
splicing misregulation is unclear. However, there is substantial evidence for the misregulation of 
splicing events by two RNA binding protein families: CUG-BP and ETR-3-Like factors (CELF) 
and MBNL proteins. The MBNL proteins have been shown to bind to RNA repeats and directly 
regulate alternative splicing of multiple pre-mRNAs including several that undergo misregulated 
alternative splicing in DM.51-55 Interestingly, CELF and MBNL proteins have been shown to act 
antagonistically in the misregulation of the splicing of two pre-mRNAs, TNNT2 (cardiac 
troponin T) and IR (Insulin receptor) in DM cells. The reduced MBNL activity is due to 
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sequestration by RNA repeats and increased CELF activity are determinative factors for 
misregulation in DM. 
Table 3-2. The list of pre-mRNAs misregulated during DM pathogenesis.45 
 
 
 
 
 
 
 
 
 
 
3. 10 Research aims  
My research project was to study the interaction between the MBNL1 protein and 
poly(CUG)RNA and the inhibition of the complex formed between MBNL1 and 
poly(CUG)RNA and poly(CCUG)RNA by small molecules. Important residues in the MBNL1 
protein were mutated to alanine by site directed mutagenesis and truncated versions of protein 
were expressed by molecular cloning approach to unravel the MBNL1 interaction with 
poly(CUG)RNA. The mutated and truncated proteins binding with pathogenic (CUG)12 repeat 
and natural target (S10 RNA) was investigated by EMSA (electrophoretic mobility shift assay). 
The small molecules inhibition of poly(CUG)RNA-MBNL1 and Poly(CCUG)RNA-MBNL1 
Pre-mRNA Mis-regulated 
exon/intron 
Cardiac troponin T 
(TNNT2 or cTNT) 
Exon 5 
Insulin receptor (IR) Exon 11 
Chloride channel 
(CLCN-1) 
Intron 2 and exon 7a 
Ryanodine receptor Exon 70 
Microtubule-associated 
Protein tau (MAPT) 
Exon 2 and 10 
Myotubularin-related 
protein 1 MTMR1 
Exon 2.1 and 2.3 
Fast skeletal troponin 
(TNNT3) 
Fetal exon 
N-methyl-D-aspartate 
(NMDAR1) 
Exon 5 
Amyloid precursor protein 
(APP) 
Exon 7 
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complexes was studied by EMSA and the binding of small molecules to RNA repeats was 
investigated by isothermal titration calorimetry experiments.  
3.11 Introduction 
Poly(CUG)RNA and poly(CCUG)RNA sequester MBNL family proteins which cause, 
misregulation of alternative splicing of 10 pre-mRNAs of which at least two (insulin receptor, 
muscle specific chloride channel (CLCN-1)) are directly related to disease symptoms.50-52 The 
three human MBNL paralogues, MBNL1/EXP, MBNL2/MBLL/MLP1 and MBNL3/MBXL are 
homologues of Drosophila muscleblind (mbl), which is required for Drosophila photoreceptor 
and muscle differentiation.56-57 Among the three MBNL proteins MBNL1 and MBNL2 are more 
abundant and have been shown to colocalize with CUG and CCUG repeats in the nucleus, 
forming nuclear foci in both DM1 and DM2.41, 49, 58-60 MBNL1 and MBNL2 are expressed in 
heart and skeletal muscle, two tissues prominently effected in DM.61 MBNL3 expression is 
restricted to placenta in adult mice and is widely expressed in the embryo.41, 58 All three proteins 
have almost identical protein sequences and appear to similarly regulate alternative splicing in 
tissue culture.54, 62-63 Each of these three proteins contain four CCCH zinc finger domains, 
positioned as tandem pairs at the N-terminal end (ZnF1 and ZnF2) and the middle (ZnF3 and 
ZnF4) of the protein (Figure 3-7 (a)). In ZnF1 and ZnF3 domains the cysteines are found in 
CX7CX6CX3H and in ZnF2 and ZnF4, the cysteines are found in CX7CX4CX3H sequences. Each 
tandem segment of vertebrate proteins are 99% identical and the most distantly related 
muscleblind proteins having only one ZnF pair share 67% identity with human MBNL1.64 The 
CCCH type zinc finger domain is also found in other RNA binding proteins65-68 including 
tristetraprolin (TTP), butyrate response factor, (CX8CX5CX3H sequence), which are involved in 
destabilization of mRNA, and U2AF (CX8CX5CX3H and CX7CX5CX3H sequences), which 
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participates in alternative splicing. The tandem CCCH domain interaction with RNA has been 
well studied for the TIS11D protein, a member of the TTP family. The recognition of single 
stranded 5’-UUAUUUAUU-3’ sequence by the CX8CX5CX3H domain of TIS11D was characterized 
by NMR. Each of the two domains recognize a UAUU repeat using stacking and hydrogen 
bonding interactions.69 
 
 
    
 
GPLGSMAVSVTPIRDTKWLTLEVCREFQRGTCSRPDTECKFAHPSKSCQVENGRVIACFDSLKG
RCSRENCKYLHPPPHLKTQLEINGRNNLIQQKNMAMLAQQMQLANAMMPGAPLQPVPMFSVAPS
LATNASAAAFNPYLGPVSPSLVPAEILPTAPMLVTGNPGVPVPAAAAAAAQKLMRTDRLEVCRE
YQRGNCNRGENDCRFAHPADSTMIDTNDNTVTVCMDYIKGRCSREKCKYFHPPAHLQAKIKAAQ
YQLEHHHHHHERPHRD 
 
Figure 3-7. (a). Schematic representation of human MBNL1 full length protein with the four 
zinc finger domains identified. The numbers indicate the length of the linker segments. (b) 
Alignment of the amino acid sequences corresponding to truncated versions of MBNL1 
(Genbank ID: NM_021038), MBNL2 (Genbank ID: NM_144778) and MBNL3 (Genbank ID: 
NM_018388) containing all four zinc finger domains. The alignment was performed using the 
program MultAlin. Identical amino acids are shown in red. (c). Amino acid sequence of the 
MBNL1N (truncated form) used in our experimental studies. The sequences that are high-lighted 
in red and green represent the zinc finger domains 1 to 4 and hexahistag, respectively. 
 
 Human full length MBNL1 is approximately 380 amino acids long with tandem zinc 
finger motifs located at the N-terminus and in the middle of the protein. Kinko et al. and Warf et 
al. previously reported the binding of MBNLl (1-260) and MBNL1 (1-382) protein to 
poly(CUG) repeats and found that the truncated protein binds similarly to the full length protein. 
(a) 
 
 
 
(b) 
 
 
 
 
 
(c) 
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These results confirmed that the C-terminal end of the protein is not important for recognition of 
CUG repeats.70-71 So, all experiments reported here were performed with the truncated protein 
containing all four zinc fingers and a His-tag at the C-terminus of the protein as shown in Figure 
3-7 (c). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-8. RNA structures used for experimental studies. The (CUG)4 and (CUG)12 are 
examples of poly(CUG)RNAs (DM1 targets) and (CCUG)6 is an example of poly(CCUG)RNA 
(DM2 target). The cTNT and S10 are the fragments of cardiac troponin T pre-mRNA, which is a 
natural target for MBNL1 protein. The sequence shown in blue box is exactly same as the 
sequence of S10 RNA. 
 
We have investigated the interaction of MBNL1N protein with poly(CUG) repeats and 
cardiac troponin T (cTNT) pre-mRNA, which is one of the natural targets of MBNL1 protein. 
MBNL1N binds to the 3’ end of the fourth intron of cTNT pre-mRNA to control splicing. The 
S10 RNA is a truncated version of cTNT RNA (Figure 3-8). The specificity of MBNL1N was 
investigated by studying its interaction with (CUG)4 and (CUG)12 poly(CUG)RNA repeats in the 
presence and absence of yeast tRNA. We used alanine scanning to identify amino acids of 
MBNL1N that significantly contribute to interactions with pathogenic RNA and S10 RNA. We 
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also investigated the ability of individual zinc finger domains in MBNL1N to bind to 
poly(CUG)RNA and S10 RNA. This study is interesting because the structure of the MBNL1N-
poly(CUG)RNA complex has not been solved and no studies have been performed to investigate 
the roles of amino acids involved in interactions with poly(CUG)RNA.  
3.12 Results and discussion 
The (CUG)4 and (CUG)12 RNAs were selected for studying the interaction of MBNL1N 
with poly(CUG)RNA. Previously, Berglund and co-workers determined the MBNL1N binding 
to (CUG)12 and (CUG)90 RNAs with similar affinity. Therefore, for our studies we selected 
shorter CUG repeats. The (CUG)4 is stabilized by an ultrastable UUCG tetraloop and the 
(CUG)12 maintains the structure by stable CG stem region. The (CCUG)6 was selected as an 
example of poly(CCUG)RNA and is stabilized by long stem (GCGG). To study the effect of 
mutated proteins and truncated MBNL1N with natural targets, we chose cTNT RNA and S10 
RNA (truncated version of cTNT RNA). As the C-terminus of MBNL1 protein is not involved in 
the recognition of RNA targets, we used the truncated version (MBNL1N) of full length protein 
containing 260 amino acids without C-terminal end.  
3.12.1 MBNL1N interaction with poly(CUG)RNA repeats and natural target 
RNAs 
The binding assays were performed by electrophoretic mobility shift assays using a 6% 
native polyacrylamide gel at 4 0C in 0.5 X Tris-Borate buffer (pH 8). The interaction of 
MBNL1N with (CUG)4  and (CUG)12 repeats was studied in the presence and absence of yeast 
tRNA. The protein recognizes (CUG)4 and (CUG)12 with binding affinities of 26 ± 4 nM and 
165 ± 9 nM, respectively. The dissociation constant (KD) of MBNL1N with (CUG)12 RNA 
agree with the previously reported value. The binding to (CUG)4 RNA is 5-fold better than to 
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(CUG)12, which may be due to the unstable secondary structure of (CUG)4 RNA. The secondary 
structure prediction analysis for (CUG)4 RNA by the program mFold suggests that it is not 
forming the same structure as shown in the Figure 3-8. MBNL1N prefers binding to single 
stranded RNA over proper duplex structure. The affinity of MBNL1N with (CCUG)6 RNA is 
100-fold better than (CUG)12 RNA, which is almost similar to binding to its natural target cTNT 
RNA.  
The binding affinities were decreased in the presence of tRNA and are proportional to the 
concentration of tRNA (Figures 3-9 and 3-10; Table 3-3). These results suggest that MBNL1N is 
not specific for poly(CUG)RNA and it may bind to other RNA targets. The MBNL1N is binding 
with the same affinity to cTNT and S10 RNAs. This indicates that the protein is not binding to 
the region located below the blue box in the 32 mer cTNT RNA (Figure 3-8).  
 
 
 
 
 
 
 
 
Figure 3-9. The representative binding curves for binding of MBNL1N protein with (CUG)4  (a)  
and (CUG)12 RNA (b). The red, blue, and green lines correspond to binding in the absence, lower 
concentration (0.2 µM and 0.9 µM for (CUG)4 and (CUG)12 RNA, respectively), and higher 
concentration (0.4 µM and 1.8 µM for (CUG)4 and (CUG)12 RNA, respectively) of tRNA, 
respectively.  
 
 
 
(a)                                                           (b) 
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Figure 3-10. Representative electrophoretic mobility shift assays of MBNL1N protein binding to 
poly(CUG)RNAs in the presence and absence of tRNA and also with cTNT and S10 RNAs. A 2 
fold serial dilutions of the protein were incubated with 32P-labeled RNAs at room temperature for 
20 min. Electrophoresis was performed using a 6% native polyacrylamide gel at 4 0C in 0.5 X 
Tris-Borate buffer (pH=8). The top and lower gel pictures represent the binding of MBNL1N 
protein in absence of tRNA. The first lane from the left represents free RNA band and the slower 
running band in the other lanes corresponds to the complex. The concentrations shown on the 
blue bar indicate lowest and highest concentrations of protein used for the experiment. 
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Table 3-3. The summary of the data for MBNL1N protein binding with poly(CUG)RNAs and 
natural targets cTNT and S10 RNAs. 
 
RNA KD (nM) 
(Without tRNA) 
KD (nM) 
(With tRNA) 
KD (nM) 
(With tRNA) 
(CUG)4 26 ± 4 69 ± 10 (0.2 µM tRNA) 92 (0.4 µM tRNA) 
(CUG)12 165 ± 9 370 ± 20 (0.9 µM RNA) 767 (1.8 µM tRNA) 
cTNT 1.4 ± 0.8   
S10 1.3 ± 0.2   
 
3.12.2 Identification of amino acids in MBNL1N that are important for 
binding to RNA 
An understanding of the binding interaction between MBNL1N protein and the 
pathogenic RNA sequences will be beneficial for the rational design of small molecules to inhibit 
the formation of the MBNL1N-RNA complexes. Currently, the binding site and the protein 
sequences necessary for binding of MBNL1N protein with poly (CUG)RNA have not been well-
characterized. Recently, Teplova and co-workers published a crystal structure of the complex 
formed between the truncated MBNL1N protein having only zinc finger 3 and 4 domains and 
CGUUGC RNA64 but no studies have been completed with poly(CUG)RNA. Sequence 
comparison of muscleblind from different species revealed the presence of two protein motifs 
other than the CCCH zinc finger domain. The first motif is a Lev box located before the first 
zinger and has the consensus sequence WLXLEV, where X indicates any amino acid. The 
second motif is located before and after the zinc finger 2 and consists of a core NGR sequence 
immediately followed by either a valine or an asparagine residue, with two additional highly 
conserved polar residues before and after the NGR core.72  
 
 
 
 67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-11. Representative electrophoretic mobility shift assays of MBNL1N mutant proteins 
binding to (CUG)12 repeat and S10 RNAs. The numbers 1, 2, 3, 4, 5, and 6 correspond to the 
Phe22Ala, Phe36Ala, Phe54Ala, Ser56Ala, Tyr68Ala, and Tyr188Ala mutants. The protein 
samples were 2 fold serially diluted, incubated with 32P-labeled RNAs at room temperature for 
20 min and the electrophoresis was performed using a 6% native polyacrylamide gel at 4 0C in 
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0.5 X Tris-Borate buffer (pH=8). The first lane from the left represents the free RNA band and 
the top band in the other lanes corresponds to complex. The concentrations shown on the blue 
bar indicate lowest and highest concentrations of protein used for the experiment.  
 
The other commonly seen structural element in all muscleblind proteins is the 
conservation of four aromatic residues in the first zinc finger pair as well as tryptophan within 
the LEV box (Figure 3-12). The tandem CCCH zinc finger domain of the TIS11d protein (a 
member of the TTP family of proteins) binds ARE (AU-rich element) sequences by intercalating 
a tyrosine and phenylalanine side chain between AU and UU dinucleotides, respectively. Hudson 
and co-workers reported that the hydrophobic and stacking interactions of aromatic rings and 
heterocyclic bases provide the basis for recognition between TIS11D and ARE RNA.69, 73 The 
mutation of cysteines and histidines (C124H, C124R, H128K, C147R, C162H, and H166L) in 
the tandem zinc finger domain of TTP resulted in a loss of protein function.68, 74  
The conserved aromatic residues in the MBNL1N protein occupy the same position 
relative to those in the TIS11d protein-ARE complexes, so these residues may be important in 
the MBNL1N interaction with RNA. We chose six amino acids Phe22, Phe36, Phe54, Ser56, 
Tyr68, and Tyr188 which are conserved in different muscleblind and zinc finger proteins and 
mutated them to alanine by site-directed mutagenesis (Figure 3-12).  
MAVSVTPIRDTKWLTLEVCREFQRGTCSRPDTECKFAHPSKSCQVENGRVIACFDSLKGRCSRE 
 
NCKYLHPPPHLKTQLEINGRNNLIQQKNMAMLAQQMQLANAMMPGAPLQPVPMFSVAPSLATNA 
 
SAAAFNPYLGPVSPSLVPAEILPTAPMLVTGNPGVPVPAAAAAAAQKLMRTDRLEVCREYQRGN 
 
CNRGENDCRFAHPADSTMIDTNDNTVTVCMDYIKGRCSREKCKYFHPPAHLQAKIKAAQYQLEH 
 
HHHHHERPHRD 
 
Figure 3-12. Amino acid sequence of MBNL1N (truncated form). The sequences which are 
high-lighted in red represent zinc finger domains 1 to 4 and the one high-lighted in blue represent 
the LEV and NGR boxes. The amino acids selected for mutation are high-lighted and underlined 
in green.  
ZNF2                          NGR box 
   ZNF3                                                             ZNF4 
 LEV box                ZNF1                               NGR box 
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The binding affinity of mutated proteins with (CUG)12 and S10 RNAs were studied by 
electrophoretic mobility shift assay. The images of the gels evaluating the binding of proteins to 
RNA are shown in Figure 3-11 and the results are summarized in Table 3-4. In general, we did 
not observe significant differences in the binding constants (KD) of the mutated proteins 
compared to the wild type protein. Two exceptions are Phe54Ala and Tyr68Ala proteins which 
bind (CUG)12 RNA with 3-fold weaker binding affinity than the wild type protein.  
Table 3-4. Summary of the binding data for the wild type and mutated proteins with (CUG)12 
and S10 RNAs. The Phe54Ala and Tyr68Ala mutants (high-lighted in blue) bind (CUG)12 RNA 
with 3-fold weaker affinity than the wild type protein. 
 
 
 
 
 
 
 
 
These results suggest that the selected residues are not essential for recognition of 
(CUG)12 and S10 RNAs. The protein may have more than one binding site for RNA targets or 
many amino acids may be involved in interactions with RNA. In these conditions the loss of 
binding affinity with the single point mutation will be compensated by other interactions. The 
other reason could be that the selected mutations may not destabilize all the zinc finger domains 
present in the protein and the properly folded zinc finger protein can bind to RNA. The other 
possibility is that the protein is too long (around 272 amino acids) and one mutation may not be 
sufficient to destabilize the whole complex. So the double or triple point mutations or mutations 
in the truncated protein (ZnF3 + ZnF4) are necessary to find out the essential amino acids 
Protein (CUG)12 
KD (nM) 
S10 
KD (nM) 
Wild type 150 ± 20 1.3 ± 0.2 
Phe22Ala 270 ± 55 1.1 ± 0.1 
Phe36Ala 388 ± 18 1.4 ± 0.1 
Phe54Ala 509 ± 50 2.0 ± 0.4 
Ser56Ala 261 ± 43 1.3 ± 0.4 
Tyr68Ala 537 ± 22 1.2 
Tyr188Ala 161 ± 10 0.9 
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involved in recognition of RNA targets. In the present study, the protein was mutated only at one 
zinc finger domain and other domains were not affected. In double or triple point mutation 
studies we can affect two or three zinc finger domains at the same time that may destabilize the 
complex. The double or triple point studies may reveal the hot spots of protein and useful in 
rational design of small molecules to inhibit the formation of MBNL1N-RNA complexes. 
3.12.3 Investigation of essential zinc finger domains for recognizing RNA 
 
The structurally distinctive feature of muscleblind like proteins is the presence of tandem 
zinc finger (TZF) domains composed of three cysteines and one histidine residue. These CCCH 
domains coordinate zinc atoms and bind to single stranded RNA in a sequence specific manner.75 
TIS11D is one of three closely related human proteins that belong to the CCCH zinc finger 
protein family76 and the structure of tandem CCCH-type zinc finger in complex with the AU rich 
element 5’-UUAUUUAUU-3’ has been determined.69 The two CCCH zinc fingers fold 
independently, and the linker is flexible in the free state, but upon binding the two domains 
arrange almost parallel to one another and form several stacking interactions with the single 
stranded RNA molecule. Unlike TIS11D, MBNL1N recognizes double stranded 
poly(CUG)RNA and no studies have been completed investigating binding to double stranded 
RNA. Therefore, it is very interesting to evaluate the contributions of the zinc finger domains to 
RNA recognition.  
The aim is to uncover the minimal zinc finger domains important for binding to 
poly(CUG)RNA. In this study, we performed a deletion analysis of MBNL1N to identify which 
fragment or fragments contribute in binding to (CUG)12 and S10 RNA. To address this question, 
we made two truncated proteins having zinc finger 1 and zinc finger 3 and 4 (Figure 3-13). The 
experimental evaluation of individual deletion mutants (ZnF1 and ZnF3 + ZnF4) binding to 
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RNA targets has been studied. The truncated peptides (ZnF1 and ZnF3 + ZnF4) did not bind to 
(CUG)12 and S10 RNA (Figure 3-14). These results suggest that the protein needs all four zinc 
finger motifs to recognize RNA. It is possible that the studied zinc finger motifs do not fold 
properly for recognizing (CUG)12 and S10 RNAs.  
 
 
 
 
 
Figure 3-13. Truncated proteins prepared for experimental studies. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-14. Representative electrophoretic mobility shift assays of deletion mutant (ZnF1 and 
ZnF3 + ZnF4) proteins binding to (CUG)12 and S10 RNAs. The protein samples were 2 fold 
serially diluted, incubated with 32P-labeled RNAs at room temperature for 20 min and 
electrophoresis was performed using a 6% native polyacrylamide gel at 4 0C in 0.5 X Tris-Borate 
buffer (pH=8). The first lane from the left is free RNA and there are no complex bands. The 
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concentrations shown at the bottom of each gel picture represent the highest concentrations of 
protein used for the experiment.  
 
3.13 Conclusion 
The recognition of MBNL1N of its natural and pathogenic RNA targets may not be 
specific because the binding affinity of the protein decreases with increasing yeast tRNA 
concentration. This suggests that the protein could bind to RNA targets other than the natural 
targets already identified. The lack of specificity could also be a reason for colocalization of 
MBNLIN protein with poly(CUG)RNA repeats. The MBNL1N binding to (CUG)4 RNA is 5-
fold better than to (CUG)12, this may be due to the unstable secondary structure of (CUG)4 RNA 
and MBNL1N binds single stranded RNA better than to a duplex. The affinity of MBNL1N with 
S10 RNA is 100-fold better than (CUG)12 RNA, which indicates it prefers natural target 
compared to pathogenic RNAs. 
Substitution of the selected amino acids Phe22, Phe36, Phe54, Ser56, Tyr68, and Tyr188 
with alanine did not result in a large destabilization of complexes formed with either 
poly(CUG)RNA or S10 RNA. One possible explanation could be that the MBNL1N protein may 
have more than one site for binding to RNA targets or the chosen amino acids are not involved in 
any interaction with RNA. Double or triple point mutations or mutations in the truncated protein 
(ZnF3 + ZnF4) may reveal the essential amino acids involved in recognition of RNA targets. It is 
clear that all the zinc finger motifs are required for binding because the truncated peptides (ZnF1 
and ZnF3 + ZnF4) do not bind to (CUG)12 or S10 RNA. Further studies can reveal the hot spots 
of protein and useful in rational design of small molecules to inhibit the formation of the 
MBNL1N-RNA complexes. 
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3.14 Materials and methods 
DNA oligomers were obtained from Integrated DNA Technologies and purified by 
ethanol precipitation. Purified RNA sequences were obtained form Dharmacon research. Yeast 
tRNA was purchased from Sigma-Aldrich. Acrylamide and bisacrylamide solutions used in 
native and denaturing gels were purchased from National Diagnostics, Inc. γ-32P ATP was 
purchased from Amersham Biosciences Corp. An expression vector for MBNL1N (1-272) and 
vectors containing (CTG)54 and (CTG)90 sequences were obtained from Maurice S. Swanson 
(University of Florida College of Medicine, Gainesville, FL).77-78  
Water was purified and de-ionized using Bio cell A10 Milli-Q by Millipore. Samples 
were centrifuged with an eppendorf 5415 C, and lyophilized using a speedvac concentrator and a 
Lyph-lock 4.5 lyophilizer by Labcon. The gel mobility shift assays were kept at constant 
temperature using a VWR 160 constant temperature bath, and gels were dried using Fisher 
Biotech gel drying system and developed using a phosphorimage screen from Molecular 
Dynamics. The gels were scanned using the Storm840 by Molecular Dynamics, and visualized 
with Image Quant 5.1 software.  
 3.14.1 Recombinant protein expression and purification 
 The proteins were over expressed in E. coli strain (BL21-CodonPlus (DE3)-RP 
competent cells (Stratagene)) containing pGEx-6P-1-MBNL1N or MBNL1N mutants or 
MBNL1N truncated forms (ZnF1 and ZnF3 + ZnF4) until the O.D600 approximately reached 0.5. 
Expression was then induced with 1 mM IPTG (isopropyl β-D-1-thioglactopyranoside) for 2 
hours at 37 oC. Bacterial cells were collected by centrifugation and were then resuspended in 
lysis buffer containing 25 mM Tris-Cl (pH=8.0), 0.5 M NaCl, 10 mM imidazole, 2 mg/ml 
lysozyme, 5% glycerol, 2 mM 2- mercaptoethanol, 0.1% Triton X-100, 1 µM pepstatin, 0.1 mM 
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PMSF (phenylmethanesulphonylfluoride), and 1 µM leupeptin. The solution was sonicated six 
times for 15-20 s pulses each with resting time of 10 s between pulses. The cell suspension was 
centrifuged at 10,000 rpm for 10 minutes and the supernatant was collected and filtered through 
a 0.45 µm Millex Filter (Millipore). 
The cell lysate was incubated with Ni-NTA agarose (QIAGEN) beads for 1 h at 4 oC and 
then the beads were washed (3 times, 15 ml each) with a washing buffer containing 25 mM Tris-
Cl (pH=8), 20 mM imidazole, 0.5 M NaCl, and 0.1% Triton X-100, followed by elution with 
elution buffer of 25 mM Tris-Cl (pH=8), 0.5 M NaCl, 250 mM imidazole and 0.1% Triton X-
100. Subsequently, 10 mM of 2-Mercaptoethanol was added to the eluate containing the GST 
fusion protein and incubated with Glutathione Sepharose 4B (GE Healthcare) for 1 hour at 4 oC. 
The beads were washed 3 times (15 ml each) with a washing buffer containing 25 mM Tris-Cl 
(pH=8), 300 mM NaCl, 5 mM 2-mercaptoethanol and 0.1% TritonX-100. The beads were 
collected and incubated with PreScission Protease (GE Healthcare) overnight at 4 oC. The 
enzyme cleaves the GST-tag, and the proteins were collected in the column flow-through and 
concentrated with a Microcon Centrifugal Filter 3000 MWCO (Millipore). The purity of the 
proteins was analyzed by SDS PAGE gel (silver and coomassie stained) (Figures 3-15 to 3-17) 
and MALDI mass spectrometry (Figures 3-18 to 3-26). The concentration of protein samples 
were determined by amino acid analysis or Bradford assay. The samples were sent to Keck 
Biotech facility at Yale University, New Haven, CT for amino acid analysis. 
3.14.2 SDS gel electrophoresis 
The MBNL1N mutant protein samples and truncated proteins were analyzed by 8% and 
17% acrylamide gels, respectively. The wild type protein was stained with silver stain and the 
other proteins samples were stained with Coomassie stain following standard protocols. The 
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upper bands observed in mutant protein SDS gel are may be due to tetramer complex of 
MBNL1N (Figure 3-16). 
 
 
 
 
 
 
 
 
Figure 3-15. Silver stained SDS gel picture for analyzing the purity of wild type MBNL1N 
protein  
 
 
 
Figure 3-16. Coomassie stained SDS gel picture for analyzing the purity of mutant MBNL1N 
proteins 
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Figure 3-17. Coomassie stained SDS gel picture for analyzing the purity of truncated MBNL1N 
protein  
 
 
 
 
 
 
 
 
 
Figure 3-18. MALDI mass spectrum of MBNL1N protein. Calculated MW: 30133. Observed 
MW: 30169 
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Figure 3-19. MALDI mass spectrum of Phe22Ala mutant protein. Calculated MW: 30040. 
Observed MW: 30021.   
 
 
 
 
 
 
 
 
 
 
 
Figure 3-20. MALDI mass spectrum of Phe36Ala mutant protein. Calculated MW: 30040. 
Observed MW: 30005.   
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Figure 3-21. MALDI mass spectrum of Phe54Ala mutant protein. Calculated MW: 30040. 
Observed MW: 30063.   
 
 
 
 
 
 
 
 
 
Figure 3-22. MALDI mass spectrum of Ser56Ala mutant protein. Calculated MW: 30010. 
Observed MW: 30083.   
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Figure 3-23. MALDI mass spectrum of Tyr68Ala mutant protein. Calculated MW: 30030. 
Observed MW: 30022.   
 
 
 
 
 
 
 
 
 
Figure 3-24. MALDI mass spectrum of Tyr188Ala mutant protein. Calculated MW: 30030. 
Observed MW: 30011.   
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Figure 3-25 MALDI mass spectrum of ZnF1 truncated protein. Calculated MW: 8079. Observed 
MW: 8098.   
 
 
 
 
 
 
 
 
 
 
Figure 3-26. MALDI mass spectrum of ZnF3+ZnF4 truncated protein. Calculated MW: 11513. 
Observed MW: 11518.   
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3.14.3 Radio labeling of 5’ end of RNA 
To a 1.5 ml screw-cap tube, 10 µl of 5 picomoles of RNA, 5 µl [γ-32P] ATP, 2 µl 10× 
kinase buffer (70 mM Tris-HCl pH 7.6, 10 mM MgCl2, 5 mM dithiothreitol, New England 
Biolabs, Inc.), 3 µl water (to bring the total volume to 20 µl) and 1 µl T4 polynucleotide kinase 
(10,000 units/ml, New England Biolabs, Inc.) added and mixed properly. 
The reaction was incubated at 37 °C for 1.5 hrs. After incubation, the reaction was diluted 
with 29 µl water to bring the total volume to 50 µl. Then the reaction mixture was extracted with 
50 µl phenol/chloroform/isoamylalcohol (25:24:1), and 50 µl of chloroform/alcohol (24:1) 
solution, respectively. The sample was vortexed for 1 min and centrifuged at 14,000 rpm for 1 
min. The lower organic layer was removed and the upper aqueous layer containing the RNA was 
left in the tube. The same procedure followed for both the extractions. The final solution was 
ethanol precipitated twice  and the RNA pellet was dried in speed vac for 20 mins, and dissolved 
in 50 µl TE buffer to obtain a 100 nM labeled RNA solution. The 100 nM RNA solution was 
further diluted by 20 fold (2.5 µl 100 nM labeled RNA solution diluted to 50  µl with TE buffer) 
to obtain a 5 nM labeled RNA solution. 
3.14.4 Equilibrium binding assays 
 RNA was labeled with [γ-32P]ATP using T4 polynucleotide kinase (New England 
Biolabs) enzyme. Labeled RNA was heated at 95 0C for 2 min and then placed on ice for 10 min 
in RNA storage buffer (66 mM NaCl, 6.7 mM MgCl2, and 27 mM Tris (pH 7.5). The protein 
(MBNL1N) was serially diluted in binding buffer (175 mM NaCl, 5 mM MgCl2, 20 mM Tris 
(pH 7.5), 1.25 mM BME, 12.5% glycerol and 2 mg/mL BSA, and 0.1 mg/mL heparin) and 5 µl 
of protein solution added to 5 ul of aliquoted RNA solution. The reaction mixture was incubated 
at room temperature for 25 min and loaded onto a 6% polyacrylamide gel (80:1) prechilled at 4 
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0C. The gels were run for 1 hr at 360V in 0.5 X Tris-Borate buffer (pH=8), dried and 
autoradiographed. The binding of all the mutants and MBNL1N wild type to different RNA 
targets were determined in the absence of tRNA. MBNL1N binding to (CUG)4 and (CUG)12 was 
also determined in the presence of yeast tRNA (The sample was prepared considering tRNA 
molecular weight as 25,000 Daltons). The gels were exposed to a phosphorimager screen for 
overnight and individual bands were quantified using ImageQuant software (Molecular 
Dynamics) and the data fit by using Kaleidagraph 3.5 (synergy) software. The apparent KD 
values were obtained by fitting fraction RNA bound versus protein concentration using the 
following equations Y = 1/(1+(m1/m0)), where Y= Fraction bound, m1=KD and m0= Protein 
concentration. 
3.14.5 Site directed mutagenesis (Alanine scanning)   
The selected six amino acids were mutated to alanine by site directed mutagenesis using 
the following forward and reverse primers for the pGEX-6P-1/MBNL1N vector. 
Phe22Ala: 
Forward Primer 5’-GTATGTAGAGAGGCCCAGAGGG-3’ 
Reverse Primer 5’-GTCCCCCTCTGGGCCTCTCTAC-3’ 
Phe36Ala: 
Forward Primer 5’-GGAATGTAAAGCTGCACATCCTTCG-3’ 
Reverse Primer 5’-CGAAGGATGTGCAGCTTTACATTCC-3’ 
Phe54Ala: 
Forward Primer 5’-ATCGCCTGCGCTGATTCATT-3’ 
Reverse Primer 5’-AATGAATCAGCGCAGGCGAT-3’ 
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Ser56Ala: 
Forward Primer 5’-CCTGCTTTGATGCATTGAAAGGC-3’ 
Reverse Primer 5’-GCCTTTCAATGCATCAAAGCAGG-3’ 
Tyr68Ala: 
Forward Primer 5’-GAACTGCAAAGCTCTTCATCCA-3’ 
Reverse Primer 5’-TGGATGAAGAGCTTTGCAGTTC-3’ 
Tyr188Ala: 
Forward Primer 5’-TATGTCGAGAGGCCCAACGT-3’ 
Reverse Primer 5’-ACGTTGGGCCTCTCGACATA-3’ 
The PCR product was analyzed by agarose gel. The agarose gel was stained with 
ethidium bromide and the bands were identified using an ultraviolet transilluminator. The PCR 
sample was mixed with the enzyme DPn1 (Invitrogen), incubated for 1 hr to cleave the original 
template, and transformed into XL1-blue competent cells (Stratagene). The transformed cells 
were plated on the agar plate containing ampicillin antibiotic. The cells were grown overnight 
and the DNA was isolated from the cell pellet using QIAquick Spin Miniprep Kit (QIAGEN). 
The mutations were confirmed by DNA sequencing analysis. 
3.14.6 Molecular cloning 
The pGEX-6P-1/MBNL1N vector was digested with BamHI and XhoI (Invitrogen), the 
5’ end was dephosphorylated with calf intestinal alkaline phosphatase (Invitrogen) enzyme and 
finally purified from an agarose gel using QIAquick Gel Extraction Kit (QIAGEN). The ZnF1 
(Met1 to Iso51) truncated protein insert was constructed by amplifying the zinc finger 1 region 
of pGEX-6P-1/MBNL1N using the forward primer 5’-CGGGATCCATGGCTGTTAGTGTCA-
3’ and the reverse primer 5’-CCGCTCGAGGATTACTCGTCCATT-3’. The PCR product was 
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digested with BamHI and XhoI (Invitrogen), purified from an agarose gel and ligated with 
pGEX-6P-1 backbone vector containing an N-terminal GST tag and C-terminal His6-tag by 
incubating with T4 DNA ligase (Invitrogen). The ZnF3+ZnF4 (Leu176 to Glu256) truncated 
protein insert was constructed by amplifying zinc finger 3 and 4 region of pGEX-6P-1/MBNL1N 
using the forward primer 5’-CGGGATCCATGTTAATGCGAACAGAC-3’ and the reverse 
primer 5’-CCGCTCGAGCTGGTATTGGG-3’ and sub-cloned into pGEX-6P-1 following the 
same procedure as for ZnF1. The inserted sequences were confirmed by DNA sequencing 
analysis and the expressed truncated proteins were analyzed by running SDS gel and MALDI 
mass spectrometry (Figures 3-17, 3-25 and 3-26).  
3.14.7 Transcription of p(CTG)54 and p(CTG)90 plasmids 
The plasmids p(CTG)54 and p(CTG)90 containing (CTG)54 and (CTG)90 sequences in 
pSP72 vector were transformed into XL1-blue competent cells and grown overnight. The cell 
suspension was centrifuged and DNA was isolated form the cell pellet using QIAquick Spin 
Miniprep Kit (QIAGEN). The plasmids were digested with BamHI (Invitrogen) and the linear 
plasmids purified with 1% agarose gel and using QIAquick Gel Extraction Kit (QIAGEN) 
(Figure 3-27). 
The linear plasmids were transcribed using Ambion MEGAscript T7 kit (incubated with 
T7 polymerase for more than 5 hrs), and the transcript was purified by phenol:chloroform 
extraction, isopropanol precipitation, and on a 6% denaturing acrylamide gel. Typically, 20 µL 
transcription reaction was mixed with 115 µL nuclease-free water and 15 µL ammonium acetate, 
and mixed thoroughly. The solution was extracted with equal volume of water saturated 
phenol/chloroform, and then with equal volume of chloroform. The aqueous phase was 
recovered and transferred in to a new tube and RNA was precipitated by adding 1 volume of 
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isopropanol and mixing well. Finally, the precipitated RNA was purified on a 6% denaturing gel 
to remove short RNA transcripts. The identity of the transcript was further confirmed by MALDI 
mass spectrometry (Figure 3-28). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-27. DNA agarose gels for the purified circular and linear (CTG)54 and (CTG)90 
plasmids. 
 
 
 
 
 
 
 
 
Figure 3-28. MALDI mass spectrum of (CUG)90 RNA. Calculated MW: 95051. Observed MW: 
93566.   
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CHAPTER 4 
Inhibition of Pathogenic RNAs-MBNL1N Complexes with Small 
Molecules 
4.1 Introduction 
As discussed in chapter 3 the disease myotonic dystrophy is caused by a deleterious gain-
of-function of either poly(CUG) or poly(CCUG)RNA. One mechanism by which the RNA 
induces pathogenesis is sequestration of the protein called MBNL1 (muscleblind-like 1). The 
depletion of this protein in the cell results in misregulation of alternative splicing of different 
pre-mRNAs, causing features of the disease. One therapeutic strategy suggested is to find a drug 
that can bind to RNA repeats and free the MBNL1N protein to perform its normal functions.1 
There have been studies focused on targeting RNA repeats with small molecules, peptides and 
oligonucleotides. The morpholino antisense oligonucelotide CAG25, which is 25 nucleotides in 
length, was used to block the binding of the MBNL1 protein. CAG25 was able to inhibit the 
interaction between poly(CUG)RNA and MBNL1N protein and reduced the overall burden of 
this toxic RNA. However, delivery of oligonucleotides is difficult, especially for multisystemic 
disorders like myotonic dystrophy.2 Pushechnikov and co-workers showed that compounds 
related to Hoechst 33258 destabilize the poly(CUG)RNA-MBNL1 complex, but the monomeric 
ligand is not specific and the pentameric ligands are too bulky for transportation into nucleus.3 
Gareiss and co-workers screened a dynamic library of peptides containing 11325 members and 
found some hits that can disrupt the poly(CUG)RNA-MBNL1 complex, but the inhibition 
constants are in low micromolar values and peptide drugs are not stable compared to small 
molecules.4 Thus, there is a need to design small molecules that can specifically bind to CUG or 
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CCUG repeats and inhibit the interaction with MBNL1 protein. We are performing this project 
in collaboration with Professor Zimmerman and his group at the University of Illinois, Urbana-
Champaign. Dr. Jonathan F. Arambula and Chun-Ho Wong designed and synthesized the small 
molecules that specifically bind to poly(CUG)RNA or poly(CCUG)RNA and I evaluated their 
affinity for RNA and ability to destabilize complexes formed between MBNL1N and  
poly(CUG)RNA and poly(CCUG)RNAs. 
4.2 Results and discussion 
4.3 Inhibition of the poly(CUG)RNA-MBNL1N complex 
4.3.1 Rational design of ligands 
Myotonic dystrophy type 1 (DM1) is most likely caused by the sequestration of MBNL1 
protein by poly(CUG)RNA. Molecules were designed and synthesized by Dr. Jonathan F. 
Arambula from the Zimmerman group to bind selectively to the U-U mismatches found in 
poly(CUG)RNA. The basis for the rational design of molecules is targeting U-U mismatches of 
poly(CUG)RNA. Two structural features of uracil were considered: (1) the hydrogen bond 
acceptor-donor-acceptor (A−D−A) motif normally paired with adenine, and (2) the aromatic 
surface of the monocyclic pyrimidine. 
Normally monocyclic uracil forms base pairs with bicyclic adenine. A U-U (T-T) 
mismatch will be destabilized in part because both residues are monocyclic. This destabilized 
site within the duplex allows for binding and recognition within the mismatch. Small monocyclic 
compounds, including melamine and triaminotriazine unit were chosen to recognize the dual A-
D-A motifs of the U-U mismatch. The insertion may occur through either the major or minor 
groove, and the symmetry of the hydrogen bonding motif depends on the type of binding mode 
(Figure 4-1).    
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 Intercalators have been well studied in the context of nucleic acid binding and bind with 
high affinity at every other base pair in accordance with the neighbor exclusion rule. Lhomme 
and co-workers studied acridine-nucleobase conjugates connected through alkyl linkers and 
found them to prefer a pi-stacked conformation in water in which they remained even when 
heated to 90 °C.5 The DNA duplex binding ability of these acridine-nucleobase conjugates was 
inversely proportional to linker length. Therefore, the conjugates of an acridine to the U-U 
recognition unit would be expected to yield compounds with higher affinity for poly(CUG)RNA 
because poly(CUG)RNA forms a stable A form duplex with many U-U mismatches in the 
structure. 
 
 
 
 
 
 
 
 
 
 
Figure 4-1. The symmetry of the hydrogen bonding motif (D-A-D) of the wedge melamine 
based on the binding mode (top). The heterocycle melamine hydrogen bonding within the U-U/ 
T-T mismatch (bottom).  
 
 Based on the previous analogies, the melamine-acridine conjugate 1 was designed to bind 
U-U/ T-T mismatches as a stacked intercalator (Figure 4-2). The melamine was designed to 
provide selectivity through recognition of the two bases of the U-U mismatch, and the acridine 
unit was induced to provide high affinity via intercalation at the mismatch site. The short alkyl 
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linker conjugating the melamine and acridine was designed to optimize the pi-stacking 
conformation that reduces affinity to the normal duplex. It was previously reported that 9-
aminoacridine and its derivatives have been shown to preferentially bind in the minor groove.6 
Therefore, it is assumed that conjugate 1 binds through the minor groove and recognition of a U-
U (T-T) mismatch may occur through the major or minor groove.  
 
 
Figure 4-2. The mode of binding for the proposed melamine-acridine conjugate (left).  The 
possible interactions of melamine-acridine conjugate with U-U/T-T mismatches through the 
proposed binding mode (right). 
 
4.3.2 Screening small molecules for inhibition of the poly(CUG)RNA-
MBNL1N complex 
 Compounds 1-4 were designed and synthesized by, Dr. Arambula in the Zimmerman 
group to bind selectively to the U-U mismatches present in poly(CUG)RNA. The initial 
screening assay evaluated the inhibition of the (CUG)4-MBNL1N complex by compounds 1-4 
using an electrophoretic mobility shift assay (EMSA). The sequences of all the RNAs used for 
inhibition studies are shown in Figure 4-3. The (CUG)4  and (CUG)12 RNAs form stable A form 
duplexes with U-U mismatches in the structures as shown in Figure 4-3. 
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All of the compounds used for the experiments were in solutions containing 10% DMSO. 
We performed a control experiment in 10% DMSO (lane 3) to confirm that the complex is stable 
under these conditions. Compounds 1 and 2 differ only in the length of the linker between the 
melamine and acridine units and 3 and 4 lacked the melamine unit (Figure 4-3). Compound 2 has 
a three carbon linker and minimally inhibited the complex, whereas compounds 3 and 4 which 
lack the triaminotriazine unit, did not inhibit the complex. Among all four compounds (1-4), 
compound 1 is the best inhibitor of the (CUG)4-MBNL1N complex. The results obtained for 
compounds 3 and 4 support the requirement of the melamine unit and the results obtained with 
compound 2 shows the important of linker length. All of these results confirm that the linker 
length and melamine units are playing a role in inhibiting the (CUG)4-MBNL1N complex. 
Actinomycin D is an anticancer agent, which was previously reported to bind to T-T mismatches 
in DNA.7 However, actinomycin D only minimally inhibited the (CUG)4-MBNL1N complex. 
Based on these results, compound 1 was selected for further investigations. 
 
 
 
 
 
 
 
 
 
Figure 4-3. (a) Sequences of RNA used for the experimental studies. 
 
(a) 
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Figure 4-3 (Cont.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-3. (b)Assay for screening molecules for destabilizing the (CUG)4-MBNL1N complex. 
Lane 1 is a control with only (CUG)4, lane 2 is (CUG)4 + MBNL1N complex, lane 3 is  (CUG)4 
+ MBNL1N + 10% DMSO, and lane 4-8 contain (CUG)4 + MBNL1N + 83.3 µM of ligands 1, 2, 
3, 4, and actinomycin D. The MBNL1N protein concentration used for the experiment is 200 nM 
(7.7 fold to KD of (CUG)4 with MBNL1N protein). 
 
4.3.3 Binding of melamine-acridine conjugate with RNA mismatches and 
tRNA 
The specificity of compound 1 for U-U mismatches was studied using isothermal titration 
calorimetry (ITC). The affinity of compound 1 for single U-U, C-C, A-A, and G-G mismatches 
was compared. The ligand 1 exhibiting a 6-, 143-, and 143-fold higher affinity towards a U-U 
mismatch compared to single C-C, A-A, and G-G mismatches, respectively. The sequences of 
the RNA duplexes used for the experimental studies are shown in the Figure 4-4.  
 
          3                                                                   4 
1                                                                    2 
(b) 
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Figure 4-4. Sequences of RNA mismatches used for the isothermal titration calorimetry 
experiment. 
  
The affinity of compound 1 towards yeast tRNA was also studied to confirm the 
specificity of the molecule. All tRNAs have a clover leaf structure with 73-90 nucleotides, and 
three large hairpin loops. The affinity of compound 1 to tRNA is 10 µM from ITC, which is 23 
fold weaker than that of 1 for (CUG)4 RNA. These results confirm that compound 1 is very 
specific in the recognition of U-U mismatches over other mismatches and prefers binding to 
(CUG)4 RNA over tRNA (Table 4-1).  
Table 4-1. Equilibrium dissociation constants for binding of ligand 1 with RNA mismatches and 
tRNA by isothermal titration calorimetry. 
 
 
 
 
 
4.3.4 Inhibition of poly(CUG)RNA-MBNL1N complexes 
 
The initial screening was performed using (CUG)4 RNA but for the dose dependent 
inhibition studies we also used longer (CUG)12 repeat sequences, because we were interested in 
RNA KD (µM) 
U-U mismatch 2.1 ± 0.2 
C-C mismatch 14 ±  2 
A-A mismatch >300 
G-G mismatch >300 
tRNA 11.4 ± 2.7 
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identifying the effect of small molecules on longer repeats. The inhibition of (CUG)4-MBNL1N 
and (CUG)12-MBNL1N complexes by compound 1 was studied in the presence and absence of 
competitor tRNA by EMSA. The sequences of (CUG)4 and (CUG)12 RNA used for experiment 
are shown in  Figure 4-3. The concentration of protein used for the inhibition experiments was 
based on the dissociation constant of poly(CUG)RNAs-MBNL1N complexes as described in 
chapter 3 (Section: 3.12.1). The concentration of protein used was that required for forming a 
100% bound complex. The inhibition of the poly(CUG)RNA-MBNL1N complex was measured 
by titrating compound 1 into a fixed concentration of complex, and a representative titration 
curve, and the inhibition assays are shown in Figure 4-5. The IC50 and inhibition constant (Ki) 
were determined using the following equations.  
B = ∆Bexp((-0.69/IC50)C) + Bf………………1 
Ki = IC50/(1+ (L/KD),………………………….2 
B is the volume of the bound RNA band in the gel, ∆B is the difference between the 
volumes of the bound RNA bands at the beginning and end of the titration, C is the concentration 
of the small molecule, and IC50 is the concentration of small molecule at which B = 1/2∆B + Bf.  
The apparent inhibition constants (Ki) were calculated from the determined IC50 values 
using the Cheng and Prussof equation 211 where, L is the concentration of protein and KD is the 
dissociation constant of the MBNL1N-RNA complex. Compound 1 inhibited the complexes 
formed between MBNL1N protein and (CUG)4 and (CUG)12 in absence of tRNA with IC50 
values of 52 ± 20 µM and 46 ± 7 µM, respectively, and Ki values of 6 ± 1 µM and 7 ± 1 µM, 
respectively. Inhibition by compound 1 was also studied in the presence of tRNA, because tRNA 
is ubiquitous in the cell and we were interested knowing the specificity of the small molecule at 
higher concentration of tRNA.  
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Figure 4-5. (A) Inhibition of the poly(CUG)RNA-MBNL1N complex in the absence and (B) the 
presence of tRNA. (C). The inhibition curves used to calculate the IC50 for the (CUG)n-
MBNL1N complexes. Lane 1 is a control with only (CUG)n + tRNA and lane 2 is (CUG)n + 
MBNL1N complex in presence of tRNA and no tRNA in any lane for the experiments in absence 
of tRNA. The blue bar represents the lowest and highest concentration of ligand 1 used for each 
experiment and the concentration in each well from 250 µM, 125 µM, 82.5 µM, 62.5 µM, 31.3 
µM, 15.6 µM, 7.8 µM, to 3.9 µM, respectively.  
 
(A) 
(B) 
1    2 
1    2 
1    2 
1    2 
(C) 
(C) 
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Compound 1 inhibited the complexes formed between MBNL1N protein and (CUG)4 and 
(CUG)12 in the presence of competitor yeast tRNA with IC50 values of 42 ± 20 µM and 43 ± 1 
µM, respectively, and Ki values of 11 ± 5 µM and 12.3 ± 0.3 µM, respectively. These values are 
not much different from those determined in the absence of competitor tRNA. The Ki value is 
higher than the binding constant of compound 1 with (CUG)4 RNA, which could be due to 
differences in the buffer conditions used for the experiments. Compound 1 specifically 
recognizes poly(CUG)RNA because the inhibition constant changed only by a factor of 2 even at 
9000 fold higher concentration of tRNA compared to (CUG)12 RNA. These results suggest that 
the compound 1 is very specific and able to inhibit the poly(CUG)RNA-MBNL1N complexes in 
low micro molar range even in the presence of high concentration of tRNA.  
Table 4-2. Equilibrium dissociation constants for complexes formed between (CUG)4 and 
(CUG)12 and MBNL1N. IC50 and Ki values for the inhibition of these complexes with compound 
1 in the absence and presence of competitor tRNA are listed.  
 
RNA tRNA 
(µM) 
KD 
(nM) 
[MBNL1N] 
(µM) 
IC50 
(µM) 
Ki 
(µM) 
(CUG)4 – 26 ± 4 0.2 52 ±  20 6 ± 2 
 0.2 69 ± 10 0.2 42 ± 20 11 ± 5 
(CUG)12 – 165 ± 9 0.93 46 ± 7 7 ± 1 
 0.9 370 ± 20 0.93 43 ± 1 12.3 ± 0.3 
 
4.3.5 Specificity of the melamine-acridine conjugate (compound 1) 
 
The specificity of ligand 1 has been further evaluated by studying its affinity to 
destabilize two unrelated RNA-protein complexes, the U1A-SL2 and Sexlethal-tra RNA 
complexes. The U1A protein is a key component of the U1 small nuclear ribonuceoprotein (U1 
snRNP) in the spliceosome. It binds to a single-stranded U1 snRNA stem loop 2 with very high 
affinity (KD ~10-11 M). The stem loop 2 RNA was selected to study the specificity of ligand 1 to 
hairpin loops, because it forms a stable hairpin loop with 10 bases in the loop region. The Sex-
lethal protein has high affinity for poly-uridine sequences found near the regulated 3’ splice site 
 105 
of the transformer pre-mRNA (tra) (Figure 4-6). Both of these proteins use RNA recognition 
motifs (RRMs) for recognizing the RNA, which are unrelated to zinc finger domains present in 
the MBNL1N protein. No inhibition of either complex was observed in the presence of ligand 1, 
the result is quite surprising and supports the specificity results from the ITC experiments. 
 The specificity of ligand 1 has also been studied for the inhibition of MBNL1N binding 
to its endogenous target (cTNT). The sequence of cTNT RNA is shown in Figure 4-3. cTNT 
contains one U-U mismatch, which could form a binding site for the small molecule. The 
dissociation constant of the cTNT RNA-MBNL1N complex is 1.4 ± 0.8 nM. The concentration 
of protein used for the inhibition assay was 10 nM. The Ki for the inhibition of the cTNT RNA-
MBNL1N complex by ligand 1 is 11.9 µM, which is just 2 fold higher than inhibition of the 
poly(CUG)RNA-MBNL1N complexes (Figure 4-7). These results suggests that the inhibition of 
the complex may be due to its interaction with the one U-U mismatch present in the cTNT RNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-6. (a) Inhibition of the Sex lethal-tra RNA complex in the presence of tRNA (8 µM) by 
ligand 1. The concentration of 1 in each well are 125 µM, 83.3 µM, 62.5 µM, 31.3 µM, 15.6 µM, 
7.8 µM and 3.9 µM. Lane 1 is a control with only tra RNA + tRNA and lane 2 contains the Sex 
lethal-tra RNA complex in the presence of tRNA. (b) Inhibition of the U1A-SL2 RNA complex 
1    2 
1    2 
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with ligand 1. The concentration of 1 in each well are 250 µM, 125 µM, 83.3 µM, 62.5 µM, 31.3 
µM, 15.6 µM, 7.8 µM and 3.9 µM. Lane 1 is a control with only SL2 RNA and lane 2 contains 
U1A-SL2 RNA complex. (C). Sequences of tra RNA and SL2 RNA used for these experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7. (A) Inhibition of the MBNL1N-cTNT RNA complex by ligand 1. Concentrations of 
ligand 1 in each well: 125 µM, 83.3 µM, 62.5 µM, 31.3 µM, 15.6 µM, 7.8 µM and 3.9 µM. Lane 
1 is a control with only cTNT RNA and lane 2 is cTNT RNA + MBNL1N complex. (b) The 
inhibition curve used to evaluate the IC50 for inhibition of MBNL1N-cTNT complex by ligand 1.  
 
4.4 Inhibition of the poly(CCUG)RNA-MBNL1N complex 
4.4.1 MBNL1N binding with (CCUG)6 RNA 
  We selected (CCUG)6 for our experimental studies, and the sequence of this 
poly(CCUG)RNA is shown in Figure 4-3. The (CCUG)6 RNA was stabilized by the GGCG 
stem. The MBNL1N binding to (CCUG)6 was studied in the presence and absence of  yeast 
tRNA. MBNL1N protein bound better to (CCUG)6 RNA compared to poly(CUG)RNAs. The 
(CCUG)6 structure is less stable compared to (CUG)12 RNA because it has a greater number of 
mismatches. The instability of the structure cause the formation more single stranded RNA, and 
MBNL1N prefers binding to single strand compared to double stranded RNA. The (CCUG)6 
RNA has another possible structure in which the G-C base pairs are flanked with alternating U-U 
and C-C mismatches and MBNL1N may have a preference for this structure. These may 
contribute to the better binding affinity of the protein to (CCUG)6 over (CUG)12 RNA. 
125 µM                                 3.9 µM 
(a)                                                                    Inhibition of MBNL1N-cTNT complex
1    2 
(b) 
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The dissociation constant of the MBNL1N protein-(CCUG)6 RNA complex is 15 ± 2 nM. 
The KD increased to 30 ± 4 nM in presence of 100 nM tRNA, showing that the binding affinity 
of the protein is decreased in presence of tRNA. The same trend was observed in binding studies 
with poly(CUG)RNAs (Chapter 4). Representative binding assays are shown in Figure 4-8. 
 
Figure 4-8. Representative electrophoretic mobility shift assays of the MBNL1N protein binding 
to (CCUG)6 RNA in the (a) absence and (b) presence of tRNA (100 nM). The protein samples 
were 2 fold serially diluted, incubated with 32P-labeled RNAs at room temperature for 20 min, 
and electrophorsed using a 6% native polyacrylamide gel at 4 0C. The first lane from the left is 
free RNA and in the remaining lanes the slowest running band corresponds to the complex. The 
concentrations shown on the blue bar indicate lowest and highest concentrations of protein used 
for the experiment. 
 
4.4.2 Ligand design 
 
Myotonic dystrophy type 2 (DM2) is caused by the sequestration of the MBNL1 protein 
by poly(CCUG)RNA. Molecules were designed and synthesized by Chun-Ho Wong from the 
Zimmerman group, to bind selectively to the U-U or C-U mismatches found in 
poly(CCUG)RNA. Ligand 1 possesses three essential features for inhibition of the complex: 1) a 
Janus-wedge (triaminotriazine or melamine with hydrogen bond donors), 2) the tetramethylene 
linker, and 3) acridine for intercalating into the RNA. Modification of each of these components 
might allow us to establish a SAR through binding and inhibition studies. Modification of these 
essential features resulted in the new molecules shown in Figure 4-9. In compounds 5 and 6 the 
wedge triaminotriazine was replaced by triaminopyrimidine, and in compound 7 the linker length 
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was increased from tetramethylene to pentamethylene. In compound 8 the aliphatic linker was 
substituted by an amide linker, and in compound 9 the tricyclic intercalator was swapped by a 
bicyclic one. Compounds 10-11 are synthetic intermediates in the synthesis of compounds 1-9 
(Figures 4-3 and 4-9). The compounds numbered 5-9 are modified versions of ligand 1, which is 
the best hit in inhibiting the poly(CUG)RNA-MBNL1N complex. The compounds 10-13 are the 
Janus-wedge units without linked to acridine moiety and the compound 14 is the acridine with 
aliphatic amine. The proposed mode of binding of triaminopyrimidine and triaminotriazine 
wedges with U-U mismatches in the major and minor grooves is shown in Figure 4-10. 
4.4.3 Screening of inhibition of the poly(CCUG)RNA-MBNL1N complex by 
small molecules 
The compounds screened for inhibition of poly(CCUG)RNA-MBNL1N complex are 
shown in Figure 4-9. The initial screening assay evaluated the inhibition of the (CCUG)6-
MBNL1N complex by EMSA using 350 nM protein concentration and the small molecules 
concentration is 100 µM. The concentration of the protein used is 23.3 fold of the KD of the 
complex of (CCUG)6 with MBNL1N protein, so that the protein is 100% bound form to the 
RNA. The compounds without an intercalator and compound 8 did not inhibit the CCUG)6-
MBNL1N complex. The best inhibiting compounds are 5 and 6, which have a 
triaminopyrimidine wedge unit and compound 14, which has no wedge unit (Figure 4-9). The 
ability of all of these compounds to inhibit the (CUG)12-MBNL1N complex was evaluated. 
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Figure 4-9. Compounds evaluated for inhibiting the poly(CCUG)6RNA MBNL1N complex. The 
ligands in red boxes were the best hits for inhibition of (CCUG)6-MBNL1N complex 
 
 
 
 
 
 
 
 
 
 
Figure 4-10. Proposed binding modes of triaminotriazine and triaminopyrimidine type ligands 
with the U-U mismatch with six hydrogen bonds from (a) the minor groove and (b) the major 
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groove. Corresponding modes for ligands binding to C-U mismatch with five hydrogen bonds 
from (c) the minor groove and (d) the major groove. 
 
Compound 5 inhibits the complex, but compound 6 does not. These results suggest that 
binding selectivity depends on the identity of the intercalator because in compound 6 the 
intercalator 9-amino-6-chloro-2-methoxyacridine was replaced by DACA (N-(2-
(dimethylamino)ethyl)acridine-4-carboxamide). Compound 5 and 6 were further studied for dose 
dependent inhibition of (CCUG)6-MBNL1N in the presence and absence of competitor tRNA.  
Compound 1 was also studied for dose dependent inhibition of (CCUG)6-MBNL1N complex. 
The inhibition of (CUG)12-MBNL1N and S10-MBNL1N complexes was also studied to 
investigate the specificity of these molecules 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 4-11. Screening for the inhibition of the (a) (CCUG)6-MBNL1N by ligands and (b) 
(CUG)12-MBNL1N complex by small molecules. Lane 1 is a control with only (CCUG)6 or 
(CUG)12, lane 2 is (CCUG)6 or (CUG)12 + MBNL1N complex, lane 3 is (CCUG)6 or (CUG)12 + 
MBNL1N complex + 10% DMSO, and from lane 4-14 is inhibition of complex with 100 µM of 
ligand 1, and 5-14, respectively. The MBNL1N protein concentration used for the (CCUG)6 and 
(CUG)12 screening assays is 350 nM and 1.5 µM, respectively. 
 
(a) 
 
 
 
(b) 
 
 
Inhibition of MBNL1N-(CCUG)6 Complex 
Inhibition of MBNL1N-(CUG)12 Complex 
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4.4.4 Inhibition of the (CCUG)6-MBNL1N complex 
The inhibition of (CCUG)6-MBNL1N complex by compounds 1, 5, and 6 was studied in 
the presence and absence of competitor tRNA by EMSA. The concentration of protein used for 
inhibition experiments was based on the dissociation constant of (CCUG)6 with MBNL1N 
protein and the binding data is shown in section 4.4.1. The inhibition of the (CCUG)6-MBNL1N 
complex was measured by titrating compounds into a fixed concentration of complex  
Compound 1 did not show any dose dependent inhibition of the complex (Figure 4-12). 
In contrast, compounds 5 and 6 inhibited the complexes formed between MBNL1N protein and 
(CCUG)6 with IC50 values of 59 ± 5 µM and 52 ± 8.4 µM, respectively, and Ki values of 2.4 ± 
0.2 µM and 2.2 ± 0.3 µM, respectively. These values did not significantly change in the presence 
of competitor tRNA (Table 4-3). The Ki values for the compounds 5 and 6 are almost identical, 
which indicates that they inhibit the complex with same efficiency and they retain their activity 
at high concentrations of tRNA. 
4.4.5 Specificity of compounds 5 and 6  
The specificity of ligands 5 and 6 was further evaluated by studying their ability to 
destabilize the (CUG)12-MBNL1N and S10-MBNL1N complexes. (CUG)12 is the target in DM1 
and S10 is a fragment of cTNT RNA, which is the natural target for the MBNL1N protein. The 
sequences of RNA used for these experiments are shown in Figure 4-3. The dose dependent 
inhibition assays for both compounds are shown in Figure 4-13. The compounds inhibit both the 
complexes at higher concentrations, but compound 6 is more specific than 5. Compound 5 
inhibited the (CUG)12-MBNL1N and S10-MBNL1N complexes with Ki values of 4.8 ± 1.4 µM 
and 6.3 ± 1.6 µM, respectively, while compound 6 inhibited (CUG)12-MBNL1N and S10-
MBNL1N complexes with Ki values of 15.4 ± 5.1 µM and >15.6 µM, respectively (Table 4-3). 
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Ligand 6 has more than 7 fold specificity for inhibiting the (CCUG)6-MBNL1N complex over 
the S10-MBNL1N complex. This is an exciting result because the compound specifically inhibits 
the MBNL1N complex formed with pathogenic RNA without affecting the complex formed with 
natural target. 
 
Figure 4-12. Inhibition of MBNL1N-(CCUG)6 complex by (a) compound 1 (b) compound 5 and 
(c) compound 6, respectively. The (d) and (e) are inhibition of the complex by compounds 5 and 
6 in presence of tRNA, respectively. The blue bar represents the lowest and highest 
concentrations of ligands used for each experiment and the concentration in each well is from 
250 µM, 125 µM, 82.5 µM, 62.5 µM, 31.3 µM, 15.6 µM, 7.8 µM, and 3.9 µM, respectively.  
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Table 4-3. Equilibrium dissociation constants for binding of MBNL1N with (CCUG)6, (CUG)12, 
and S10 RNAs; and IC50 and Ki values for inhibition of these complexes by compounds 5 and 6 
in the absence and presence of competitor tRNA. The compound 6 has better specificity and the 
values are high-lighted in red. 
 
RNA tRNA 
(nM) 
KD 
(nM) 
[MBNL1N] 
(nM) 
IC50 
 (µM) 
5 
IC50 
(µM) 
6 
Ki 
(µM) 
5 
Ki  
(µM) 
6 
(CCUG)6 - 15 ± 2 350 59 ±  5 52 ±  8.4 2.4 ±  0.2 2.2 ± 0.3 
 
100 30 ± 4 350 39.9 ± 11.5 35 ±  3.4 3.2 ±  0.9 2.8 ± 0.3 
(CUG)12 - 150 ± 20 1000 36.5 ± 10.6 118 ±  39.6 4.8 ±  1.4 15.4 ± 5.1 
S10 - 1 ± 0.2 15 100.6 ± 26.1 >250 6.3 ±  1.6 > 15.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-13. Inhibition of S10-MBNL1N complex by (a) compound 5 (b) compound 6, 
respectively. Inhibition of (CUG)12-MBNL1N complex by (c) compound 5 (d) compound 6, 
respectively. The blue bar represents the lowest and highest concentrations of ligands used for 
each experiment and the concentration in each well is from 250 µM, 125 µM, 82.5 µM, 62.5 µM, 
31.3 µM, 15.6 µM, 7.8 µM, and 3.9 µM, respectively.  
 
4.5 Conclusion 
Compound 1 is the first small molecule to selectively inhibit the poly(CUG)RNA-
MBNL1N complex. Compound 1 has high affinity for RNA duplexes with U-U mismatch, but 
binds with much lower affinity to RNA duplexes with C-C or A-A or G-G mismatches. Low 
micromolar concentrations of compound 1 destabilize complexes formed between toxic 
poly(CUG)RNA sequences and MBNL1N in the presence of competitor tRNA. The compound 
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has very high selectivity because it did not inhibit the (CCUG)6-MBNL1N complex, even though 
this RNA has C-U mismatches, which is very similar to U-U mismatches. Compound 1 did not 
destabilize unrelated RNA-protein complexes (U1A-SL2 and Sex lethal-tra RNA).8 
Compounds 5 and 6 successfully destabilized the complex formed between (CCUG)6 and 
the MBNL1N protein. Compound 6 is more specific than compound 5. The Ki values are not 
affected by presence of high concentrations of tRNA. These compounds have ≈ 3-fold better Ki 
in inhibiting the complex formed between MBNL1N protein with pathogenic RNAs than 
compound 1. Compound 6 has more than 7-fold selectivity in destabilizing the MBNL1N protein 
complex with (CCUG)6 compared to natural target S10 RNA. Thus compounds 1 and 6 are 
potential lead compounds for targeting DM1 and DM2, respectively. The selectivity and affinity 
of these compounds can be increased by modifying or replacing the acridine or triaminotriazine 
or triaminopyrimidine units. Affinity to longer repeats can be achieved by oligomerization of the 
compounds. 
4.6 Experimental section  
4.6.1 Materials and methods 
Purified RNA sequences were obtained from Dharmacon Research. Yeast tRNA was 
purchased from Sigma-Aldrich. Acrylamide and bisacrylamide solutions used in native and 
denaturing gels were purchased from National Diagnostics, Inc. γ-32P ATP was purchased from 
Amersham Biosciences Corp. An expression vector for MBNL1N (1-272) was obtained from 
Maurice S. Swanson (University of Florida College of Medicine, Gainesville, FL).  
4.6.2 Inhibition assay    
Gel mobility shift assays or EMSA were used to determine the IC50 and Ki of small 
molecules for RNA-protein complexes. RNAs were labeled with [γ-32P] ATP using T4 
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polynucleotide kinase (New England Biolabs). Labeled RNA sequences were heated at 95 0C for 
2 min and then placed on ice for 10 min in RNA storage buffer (66 mM NaCl, 6.7 mM MgCl2, 
and 27 mM Tris (pH 7.5). The protein (MBNL1N) was serially diluted in binding buffer (175 
mM NaCl, 5 mM MgCl2, 20 mM Tris (pH 7.5), 1.25 mM BME, 12.5% glycerol and 2 mg/mL 
BSA, and 0.1 mg/mL heparin),9 and 5 µL of protein solution was added to each 5 µL (0.2 nM) 
aliquot of RNA. The reaction mixture was incubated at room temperature for 25 min, after which 
the small molecule was added to the RNA-protein complex and incubated for 10-15 minutes at 
room temperature. The samples were loaded onto a 6% polyacrylamide gel (80:1) prechilled at 4 
0C. The gels were run for 1 hr at 360V in 0.5 X Tris-Borate buffers and dried. The gels were 
exposed to a phosphorimager screen overnight and individual bands were quantified using 
ImageQuant software (Molecular Dynamics) and the data was fit using KaleidaGraph 3.5 
(synergy) software. The bound ligand (cpm) versus small molecule concentration was evaluated 
using the following equation to determine IC50 values.10 
B = ∆Bexp((-0.69/IC50)C) + Bf 
B is the volume of the bound RNA band in the gel, ∆B is the difference between the volumes of 
the bound RNA bands at the beginning and end of the titration, C is the concentration of the 
small molecule, and IC50 is the concentration of small molecule at which B = 1/2∆B + Bf. The 
apparent inhibition constant (Ki) were calculated from the determined IC50 values using the 
Cheng and Prussof equation:11 Ki = IC50/(1+ (L/KD), where L is the concentration of protein and 
KD is the dissociation constant of the MBNL1N-RNA complex. 
The specificity of ligand 1 was studied using the above procedure except for the 
following changes. The U1A and sex lethal proteins were expressed as hexa-his constructs and 
were purified using a Ni-NTA column from Qiagen. Gel shift assays for the U1A-SL2 RNA 
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were performed as reported previously.12 The 32P-labeled SL2 RNA (0.2 nM) was incubated with 
200 nM U1A protein for 30 min at room-temperature in a buffer containing 10 mM Tris-HCl, pH 
7.4, 0.5% Triton X-100, 1 mM EDTA, and 250 mM NaCl. After the addition of glycerol to a 
final concentration of 5%, the bound and free RNA were separated using a 8% polyacrylamide 
gel at 25 °C (80:1 acrylamide/ bisacrylamide,) in 100 mM Trisborate pH 8.3, 1 mM EDTA, 0.1% 
Triton X-100 for 30 min at 360 V. Sex lethal-tra RNA complex inhibition assays were performed 
in 15 mM HEPES, pH 7.6, 50 mM potassium chloride, 1 mM EDTA, 1 mM β-mercaptoethanol, 
20 % glycerol, and 0.005% Triton-X, with 0.2 µg/µL t-RNA with 300 nM Sex lethal protein and 
0.2 nM 32P-labeled tra RNA. 
4.6.3 Isothermal titration calorimetry experiments 
ITC experiments were performed at 25 0C on a MicroCal VP-ITC (MicroCal, Inc., 
Northampton, MA). A standard experiment consisted of titrating 10 or 20 µM of RNA duplex 
(1.42 mL in sample cell) with 10 µL of 500 µM of ligand solution in syringe. The standard 
experiment was accompanied by a corresponding control experiment in which aliquots (10 µL) 
of ligand 1 (500 µM) titrated into buffer (20 mM MOPS pH=7, 300 mM NaCl) alone. The 
duration of each injection was 24 s, and the spacing between two injections was 300 s. The initial 
delay prior to first injection was 60 s. The instrument measured the heat released for each 
injection in µcal/sec. The heat associated with each injection was measured by determining the 
area under the curve by using Origin version 5.0 software (Microcal, Inc., Northampton, MA, 
USA). The heat of ligand binding for each injection was determined by subtracting ligand 
solvation (Buffer titrated with ligand) from the corresponding heat associated with ligand-RNA 
injection to yield the heat due solely to ligand binding for each injection. Binding constants were 
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determined from plots of the heat of ligand binding as a function of ligand-RNA molar ratio. The 
graph was fit using a sequential two-site binding model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-14. Plots of data representing the binding of ligand 1 with different mismatch RNA 
duplexes and tRNA by ITC experiment. The experimental conditions and the sequence of RNA 
used are shown on the left side of each binding data curve.  
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Figure 4-14 (Cont.) 
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duplexes and tRNA by ITC experiment. The experimental conditions and the sequence of RNA 
used are shown on the left side of each binding data curve.  
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Figure 4-14. Plots of data representing the binding of ligand 1 with different mismatch RNA 
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